{"id": "1adc970c-d433-44d0-aa09-d3834986f7a2", "result": " Contradiction\n\nThe primary trial results provide event-free survival percentages of 87-89% for the exemestane cohort and 88-90% for the anastrozole cohort. \n\nThese ranges show overlap between the results of the two cohorts. There is no information given that directly states or implies a 13.2% difference.\n\nSince the ranges provided allow for similarities rather than a fixed 13.2% difference, the statement cannot be directly entailed or supported by the data presented. Therefore, the statement \"there is a 13.2% difference between the results from the two the primary trial cohorts\" contradicts the information provided in the clinical trial results."}
{"id": "6b9162d0-0816-46d4-81af-c60028dcc63b", "result": " Entailment\n\nThe primary trial specifically excludes patients with a \"cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal)\". \n\nMeanwhile, the secondary trial does not mention ejection fraction as an exclusion criteria. The only requirement is that patients be premenopausal women 55 years of age or younger.\n\nTherefore, the statement that \"Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over\" can be directly entailed from the eligibility criteria presented for each trial. The answer is entailment."}
{"id": "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f", "result": " Contradiction\n\nThe adverse events reported in the primary trial include Enterocolitis 1/167 (0.60%) and Enterocolitis haemorrhagic 1/167 (0.60%). \n\nThe secondary trial adverse events do not mention Enterocolitis at all.\n\nSince Enterocolitis is only reported in a very small percentage (0.60%) in the primary trial and not reported at all in the secondary trial, the statement that \"a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis\" is contradicted by the adverse event data provided.\n\nTherefore, the answer is Contradiction, as the statement cannot be directly entailed based on the numbers reported for adverse events in each trial."}
{"id": "cc1f712a-2116-4e40-9810-f315e3fa5ff8", "result": "  Entailment\n\nThe primary trial results provided only report on local control using ipsilateral breast tumor recurrence rates at 2 years following treatment completion for a specific arm. \n\nNo information is given on progression-free survival (PFS) or objective response rate for the cohort. \n\nTherefore, the statement that \"the primary trial does not report the PFS or objective response rate of its patient cohort\" can be directly entailed from the limited results provided in the primary trial report. \n\nThe answer is entailment, as the information contained in the clinical trial results section substantiates the statement about what outcome measures were not reported."}
{"id": "904061c0-14fa-4f13-9118-9a41e24fa8eb", "result": " Contradiction\n\nThe inclusion criteria for the primary trial specifically excludes patients with the following:\n\n- Prior treatment with fulvestrant\n- Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor\n\nTherefore, the statement \"Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial\" is contradicted by the exclusion criteria presented in the eligibility section. \n\nThe answer is contradiction, as prior treatment with fulvestrant or a PI3K inhibitor is explicitly mentioned as excluding a patient from participating in the primary trial."}
{"id": "43ee7645-ce1e-42d5-9a74-3e379f6f367b", "result": " Contradiction\n\nThe eligibility criteria for the primary trial state that patients with HER2-positive status are excluded, i.e.:\n\n- HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study).\n\nTherefore, the statement \"only patients with a HER2-positive status can take part in the primary trial\" is contradicted by the exclusion criteria presented in the eligibility section. \n\nThe eligibility section explicitly mentions that HER2-positive patients are not eligible for the trial.\n\nThus, the answer is contradiction, as the given statement cannot be directly entailed based on the inclusion/exclusion criteria provided."}
{"id": "0cef8c8e-7986-46c7-a597-c5733a9899c0", "result": " Contradiction\n\nThe primary trial results report the median PFS for each cohort, along with the 95% confidence intervals. \n\nIt does not provide data on the shortest PFS time for each cohort. \n\nThe statement claims specifics about the shortest PFS for each cohort that are not stated or can be directly entailed based on the information given in the results section.\n\nTherefore, the statement \"the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months\" cannot be supported and contradicts the trial results. \n\nThe answer is contradiction, as the numbers reported do not substantiate the statement made."}
{"id": "43ce26e5-03fa-4e9d-b0eb-6ea356295753", "result": " Entailment\n\nThe intervention sections for both cohorts (HER2+ TC and HER2+ C) state that post-operatively, participants received further cycles of treatment for a maximum of 17 overall cycles. \n\nIt also specifies that each treatment cycle lasts 3 weeks.\n\nTherefore, the statement \"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks\" can be directly substantiated based on the intervention details provided for the two cohorts.\n\nThe answer is entailment, as the numbers reported in the trial section support the statement made."}
{"id": "3facad41-0221-42f8-834d-470e65c4aad5", "result": " Contradiction\n\nThe primary trial results specified that the outcome measurements were:\n\n1) Progression-free survival (PFS) \n\n2) To evaluate safety of the Trastuzumab, Bevacizumab and Docetaxel regimen\n\nThe statement claims the outcome measurement was \"The length of time during and after the treatment that a patient survives with the disease\". However, this describes an overall survival measurement, not PFS. \n\nPFS and safety evaluation are clearly defined as the outcome measurements in the results section. Therefore, the statement cannot be directly entailed and contradicts the trial information provided.\n\nMy answer is contradiction, as the outcome measurement stated does not match what is reported in the results."}
{"id": "9cbc00e9-3a2d-4471-a93e-72c95132fb6a", "result": " Entailment\n\nThe adverse events section reports adverse event data for two cohorts:\n\nCohort 1 (N=35): \nCongestive heart failure 1/35 (2.86%)\n\nCohort 2 (N=40):  \nCongestive heart failure 0/40 (0.00%)\n\nThe statement says \"The only case of congestive heart failure in the primary trial occurred in cohort 1\".\n\nThis can be directly substantiated based on the adverse event numbers reported - which show 1 case of CHF in cohort 1 and 0 cases in cohort 2.\n\nTherefore, the statement can be directly entailed from the adverse event data provided. \n\nThe answer is entailment, as the numbers support the statement about where the single case of congestive heart failure occurred."}
{"id": "8b91cab9-d858-45f3-bf8d-3d6fc55b4818", "result": "  Entailment\n\nThe results section reports on two outcome measurements for the diagnostic intervention:\n\n1) Proportion of SNs (PTc) detected by Tc method: 0.86 \n\n2) Proportion of SNs (PICG) detected by ICG method: 0.95\n\nThe statement says \"The the primary trial results section reports two different measurements\". \n\nThis can be directly substantiated based on the two outcome measurements reported in the results.\n\nTherefore, the statement that the results section reports two different measurements can be directly entailed from the trial results provided.\n\nThe answer is entailment, as the numbers support the statement about two measurements being reported."}
{"id": "4a75574c-fa86-4e62-a210-81c7b98a3807", "result": " Contradiction\n\nThe eligibility criteria state several exclusions related to disease stage:\n\n- No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer \n\n- No distant metastases \n\n- T1-3, N0-2, M0\n\nA T4 N2 M4 stage would be excluded based on:\n\n- T4 disease criteria \n- Presence of distant metastases (M1)\n\nTherefore, the statement that \"T4 N2 M4 patients are eligible for the primary trial\" is directly contradicted by the eligibility criteria provided.\n\nThe answer is contradiction, as T4 N2 M4 staged patients do not meet the criteria stipulated in the trial information."}
{"id": "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7", "result": " Contradiction\n\nThe primary trial results section only reports outcomes for one cohort/arm:\n\n- Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) \n\nIt provides measurement results for this single arm.\n\nThe statement claims the results section reports measurements for \"all 3 cohorts\". However, there is no information provided about 3 cohorts in the results section.\n\nSince the results only describe one cohort's outcomes, the statement that results are reported for all 3 cohorts cannot be directly entailed. \n\nTherefore, the answer is contradiction, as the number of cohorts mentioned in the statement does not match what is presented in the results."}
{"id": "b0b61978-57db-4a1c-812c-509e8b05f2dc", "result": " Entailment\n\nThe intervention section describes two cohorts:\n\n1) Nivolumab + Daratumumab (TNBC) \n2) Nivolumab + Daratumumab (NSCLC)\n\nThe statement says: \"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have\".\n\nThis can be directly substantiated based on the intervention details provided:\n\n- Both cohorts receive the same dosages and schedule of Nivolumab and Daratumumab\n- The only difference specified is that cohort 1 has TNBC and cohort 2 has NSCLC\n\nTherefore, the statement is directly entailed by the intervention descriptions, as it accurately reflects that the interventions are identical between cohorts and the only difference is cancer type.\n\nThe answer is entailment, as the details support the statement about the similarities and single difference between the two cohorts."}
{"id": "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1", "result": " Contradiction\n\nThe eligibility criteria specify the following:\n\n- Phase 1 inclusion requires a histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ. \n\n- Phase 2 inclusion requires the tumor is visible and enhances on prone MRI and is >1 cm, and is non-palpable. \n\nThe statement claims patients must have a \"palpable carcinoma\". However, the criteria explicitly include non-palpable tumors in Phase 2.\n\nTherefore, having a palpable tumor is not an absolute requirement based on the eligibility details provided. \n\nThe statement cannot be directly entailed and is contradicted by Phase 2 allowing non-palpable tumors.\n\nMy answer is contradiction, as palpability is not uniformly stipulated as an inclusion criterion across both phases of the trial per the information given."}
{"id": "fbb62216-2cf2-4813-ad41-12a86940610f", "result": " Entailment\n\nThe adverse events section reported:\n\nCohort 1 (N=199):\n- Anaemia 7/199 (3.52%) \n- Total adverse events 59/199 (29.65%)\n\nCohort 2 (N=36):\n- Anaemia 2/36 (5.56%)\n- Total adverse events 16/36 (44.44%)\n\nThe statement says \"Anaemia was the most common adverse event in cohort 1 and 2\".\n\nThis can be directly substantiated based on the adverse event frequencies reported - anaemia had the highest recorded rate in both cohorts.\n\nTherefore, the statement is directly entailed by the adverse event data provided.\n\nThe answer is entailment, as the numbers support that anaemia occurred most frequently in both cohorts as stated."}
{"id": "961a956e-fece-4baa-a2ad-d3a5320bd9d2", "result": " Contradiction\n\nThe primary trial results report the median PFS for each cohort, along with the 95% confidence intervals.\n\nCohort 1 (NK105): Median PFS 8.4 months (7.0 to 9.9 months)  \nCohort 2 (Paclitaxel): Median PFS 8.5 months (6.9 to 11.5 months)\n\nIt does not provide data on the shortest PFS time for each cohort. \n\nThe statement claims the shortest PFS in cohort 1 was less than 3 weeks. However, this cannot be directly supported or entailed based on the information given in the results section, which reports median PFS in months.\n\nTherefore, the statement contradicts the trial results, as the numbers reported do not substantiate the claim about the shortest PFS time.\n\nThe answer is contradiction."}
{"id": "97fd111c-6969-43ab-93af-b3dff09960e5", "result": " Contradiction\n\nThe adverse events section provided reports: \n\nAdverse Events 1:\nTotal: 0/0\n\nThe statement claims \"The adverse events section in the primary trial reports the incidence rate of 12 different AEs\".\n\nHowever, the adverse events data given only lists a total count of 0 events out of 0 participants for Adverse Events 1. \n\nIt does not provide incidence rates for 12 different adverse events as the statement suggests.\n\nTherefore, the information given cannot directly support or entail the statement about 12 AEs being reported. \n\nThe answer is contradiction, as the actual adverse events data provided does not match what is claimed in the statement."}
{"id": "eb1bfb08-eba0-4130-b328-00f56c0f84a6", "result": " Contradiction\n\nThe provided adverse events data from the primary and secondary trials are:\n\nPrimary trial (N=65):\n- Diarrhoea 5/65 (7.69%)\n\nSecondary trial (N=472): \n- No incidence of diarrhoea reported\n- Total adverse events 173/472 (36.65%) \n\nSecondary trial (N=238):\n- No incidence of diarrhoea reported \n- Total adverse events 40/238 (16.81%)\n\nThe statement claims diarrhoea is the most common AE in both trials. However, the secondary trial data does not report any instances of diarrhoea.\n\nTherefore, the statement cannot be directly entailed from the adverse event information given. It is contradicted by the secondary trial not reporting diarrhoea.\n\nThe answer is contradiction, as the numbers do not consistently support diarrhoea being the most frequent AE across both trials."}
{"id": "b1219e71-fbf5-4bba-8a93-a27ae444e3e1", "result": " Entailment\n\nThe eligibility criteria state:\n\nInclusion Criteria:\n- Confirmed hormone receptor positive advanced breast cancer, postmenopausal women \n\nExclusion Criteria: \n- Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).\n\nThe statement says: \"to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer\"\n\nThis directly matches the inclusion and exclusion criteria provided:\n\n- Inclusion requires hormone receptor positive advanced breast cancer  \n- Exclusion criteria rules out previous treatment for advanced breast cancer specifically  \n\nTherefore, the eligibility details directly support and entail the statement about what is required for patient eligibility in the primary trial.\n\nThe answer is entailment, as the trial eligibility information substantiates the claims made in the statement."}
{"id": "f10f3b84-e039-4a02-a98b-86d149d9a16f", "result": "  Entailment \n\nThe eligibility criteria state the following exclusion:\n\n- Being treated with flucytosine\n\nThe statement says \"ongoing flucytosine treatments are not permitted for participants of the primary trial\".\n\nThis can be directly substantiated based on the exclusion criteria provided, which explicitly rules out being treated with flucytosine.\n\nTherefore, the statement is directly entailed by the trial eligibility criteria. Ongoing flucytosine treatment is incompatible with the exclusion rules outlined.\n\nThe answer is entailment, as the exclusion description supports the statement about flucytosine not being permitted."}
{"id": "0ddb07ae-6e70-436d-8723-f609e59c57da", "result": " Entailment\n\nThe intervention section states that INTERVENTION 1 is:\n\nPralatrexate \nStudy drug 190 mg/m^2 for 2 to 4 weeks.\n\nThe statement says that primary trial participants receive doses of Pralatrexate calculated based on bodyweight.\n\nThe dose specification of 190 mg/m^2 directly indicates that the dose is calculated based on body surface area, which is derived from height and weight. \n\nTherefore, the statement that the dose is calculated based on bodyweight can be directly substantiated and entailed from the intervention detail provided of 190 mg/m^2.\n\nThe answer is entailment, because the unit of mg/m^2 used in the intervention supports that the dose accounting is based on bodyweight, as claimed in the statement."}
{"id": "c10eea1a-5768-442d-ae07-20b4f8f4b583", "result": " Contradiction\n\nThe eligibility criteria specify the following:\n\n- Inclusion requires HER-2 positive BC as defined by IHC/ISH scores \n\nIt does not mention triple negative breast cancer (TNBC) as an eligibility requirement. \n\nMoreover, some of the exclusion criteria would not apply to TNBC patients, such as prior treatment with trastuzumab.\n\nThe statement claims only TNBC patients are eligible. However, the provided eligibility information explicitly includes HER2-positive BC and does not restrict to triple negative disease.\n\nTherefore, the statement cannot be directly substantiated or entailed by the eligibility details given. It is directly contradictory.\n\nMy answer is contradiction, as the trial criteria support eligibility for HER2-positive BC and do not limit it only to triple negative disease as stated."}
{"id": "2ef186d0-b4ab-44de-b785-a63e9e95851a", "result": " Entailment\n\nThe adverse events sections report:\n\nPrimary trial:\n- Enterocolitis 1/167 (0.60%) \n- Enterocolitis haemorrhagic 1/167 (0.60%)\n\nSecondary trial: \n- No reports of Enterocolitis\n\nThe statement says \"most participants in the secondary trial and the primary trial did not suffer from Enterocolitis\".\n\nBased on the numbers provided:\n\n- Primary trial Enterocolitis incidence was 1/167 = 0.60%  \n- Secondary trial did not report any Enterocolitis\n\nTherefore, the numbers directly support and entail the statement that most participants did not suffer from Enterocolitis in both trials, as the incidence rates reported are low.\n\nThe answer is entailment, as the adverse event frequencies substantiate the claim made."}
{"id": "fef5aedb-21c0-4130-b8a3-cb1df5017c7a", "result": " Entailment\n\nThe adverse events section provided reports:\n\nAdverse Events 1: \nTotal: 0/0\n\nThe statement says \"The adverse events section in the primary trial is empty\".\n\nSince the only information given in the adverse events section is:\n\nAdverse Events 1:\nTotal: 0/0\n\nAnd there are no other details listed, this directly matches the statement that the adverse events section is empty.\n\nTherefore, the statement can be directly substantiated and entailed by the adverse events data shown, which contains no reported events.\n\nThe answer is entailment, as the content or lack of content in the adverse events section supports the claim made in the statement.\n\nIn summary, the statement that the adverse events section is empty is directly demonstrated by the trial information provided only listing a total of 0/0 with no other data."}
{"id": "2655c892-216e-4b96-a8f2-6f64403215c5", "result": " Entailment\n\nThe primary trial adverse events section reports:\n\nAdverse Events 1: \nTotal: 4/65 (6.15%)\nThrombocytopenia * 0/65 (0.00%) \nAnaemia * 0/65 (0.00%)\nFebrile neutropenia * 0/65 (0.00%)\nLeukopenia * 0/65 (0.00%)\nNeutropenia * 0/65 (0.00%)\nPericardial effusion * 0/65 (0.00%)\nTachycardia * 0/65 (0.00%)\nNausea * 0/65 (0.00%)\nVomiting * 1/65 (1.54%)\nConstipation * 0/65 (0.00%) \nAbdominal pain * 0/65 (0.00%)\n\nThe statement says there were 4 types of adverse events which did not affect any patients in cohort 1.\n\nReviewing the incidence rates of 0/65 for several AEs directly supports and entails this statement. Specifically, thrombocytopenia, anaemia, febrile neutropenia, leukopenia, neutropenia, pericardial effusion and tachycardia align with the claim of 4 AEs not reported.\n\nTherefore, the adverse event frequencies substantiate the statement. The answer is entailment."}
{"id": "2825d63b-8f22-4fb8-829f-9567845251c6", "result": "  Contradiction\n\nThe eligibility criteria specify:\n\n- Inclusion requires female gender \n\n- No mention of including children/pediatric patients\n\nThe statement claims both adults and children can take part. However, the criteria only supports female adult patients being eligible by specifying gender as female with no age limitations beyond \"Age 18 years\".\n\nTherefore, the portion about children being able to participate cannot be directly entailed or substantiated from the eligibility details provided, which focus on female adult patients. \n\nThe answer is contradiction, as including children is not mentioned and contradicts the criteria specifying female gender only. The trial eligibility does not support the full scope of patients proposed in the statement."}
{"id": "6b35bc10-f591-4b84-abac-40a74be949fa", "result": " Entailment\n\nThe eligibility criteria specify the following exclusion criteria:\n\n- Prior treatment with fulvestrant\n- Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor\n\nThe statement says \"Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial\".\n\nThis can be directly substantiated based on the exclusion criteria provided, which explicitly rule out prior treatment with fulvestrant and PI3K inhibitors.\n\nTherefore, the statement is directly entailed by the trial eligibility criteria. Prior fulvestrant or PI3K inhibitor treatment is incompatible with the exclusion rules outlined. \n\nThe answer is entailment, as the exclusion description supports the statement about these treatments not being permitted."}
{"id": "a5baab2c-9c32-4301-a574-4ba5a0c2eb00", "result": " Contradiction\n\nThe primary trial eligibility criteria specify that patients must have:\n\n- Presence of hot flashes for 30 days prior to study registration \n\nThe secondary trial eligibility does not mention any criteria related to hot flashes.\n\nThe statement claims hot flashes must be present for at least 4 months prior to registration for BOTH trials. \n\nHowever, the primary trial only requires 30 days and the secondary trial does not specify any criteria about hot flashes.\n\nTherefore, the 4 month requirement mentioned in the statement cannot be directly substantiated or entailed by the eligibility details provided for the two trials. \n\nThe answer is contradiction, as the trial criteria do not support the unified 4 month hot flash presence specified in the statement for both trials."}
{"id": "70677d5f-7022-404c-8410-d1f89366d92f", "result": " Contradiction\n\nThe primary trial results measure and report:\n\n- Number of Patients With Pathological Complete Response Rate\n\nThe secondary trial results measure and report: \n\n- Disease Free Survival. Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years\n\nThe statement claims both trials measure pCR and tumor diameter. However, the primary trial only reports pCR and the secondary trial only reports disease free survival. \n\nTumor diameter is not assessed in either trial results sections. Moreover, the metrics measured are different between the two trials.\n\nTherefore, the statement that both trials measure pCR and tumor diameter cannot be directly entailed or substantiated from the results data provided. \n\nThe answer is contradiction, as the results do not support measuring both metrics in both trials as stated. The metrics assessed differ between the primary and secondary trials."}
{"id": "f46a7d27-a94f-4389-a1a0-4a8f5177b354", "result": " Contradiction \n\nThe primary trial adverse events section reports:\n\nAdverse Events 1:\nAnaemia * 4/100 (4.00%)\n\nThis adverse event of anaemia affected 4 patients.\n\nThe statement claims that none of the individual adverse events recorded affected more than 1 patient. \n\nHowever, the reported rate of 4.00% for anaemia contradicts this, as it shows it affected 4 patients.\n\nTherefore, the adverse event data does not entirely support the statement, since anaemia is reported as affecting more than 1 patient.\n\nThe answer is contradiction, as the incidence rates contradict the statement that no individual AE affected more than 1 patient."}
{"id": "fe876bb0-7ce3-4197-81ad-920f1f77938e", "result": " Entailment\n\nThe primary trial results reported:\n\n- Exemestane arm event-free survival percentage: 88 (87 to 89)\n- Anastrozole arm event-free survival percentage: 89 (88 to 90) \n\nThe statement claims \"there is a minimal difference between the results from the two the primary trial cohorts\".\n\nThe reported event-free survival percentages and confidence intervals for the two arms have a difference of only 1% between them (88-89% vs 89-90%).\n\nThis small numerical difference directly supports there being a \"minimal difference\" in results as stated.\n\nTherefore, the statement can be directly entailed based on the numerical outcome values provided in the primary trial results section.\n\nThe answer is entailment, as the small magnitude of difference quantified in the trial results substantiates the statement."}
{"id": "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929", "result": "  Contradiction\n\nThe eligibility criteria state:\n\n- Age between 18-70 years \n- Karnofsky performance status index > 80%\n- Adequate hepatic, renal and heart functions\n- Adequate hematology levels\n\nThe statement claims eligibility requires:\n\n- Over 18 years old \n- Have a severe disability\n- Adequate organ/hematology functions\n\nHowever, a severe disability contradicts the performance status requirement of >80%. \n\nAlso, no mention is made of allowing disabilities in the criteria. \n\nWhile organ/blood requirements align, the disability clause introduced in the statement is not supported.\n\nTherefore, the statement cannot be entirely entailed as the eligibility details do not accommodate or imply acceptance of severe disabilities. \n\nThe answer is contradiction, as a key component of the statement is not substantiated by the actual trial eligibility provided."}
{"id": "4f705481-5dd0-414c-b375-c56e8c235b42", "result": " Entailment\n\nThe adverse events section reports:\n\nSkin infection 2/41 (4.88%)\n\nAll other adverse events are reported as affecting 1/41 patients (2.44% incidence each) \n\nThe statement claims \"The most common adverse event in the primary trial was skin infection\"\n\nSkin infection is the only adverse event reported to affect more than one patient (2 patients, or 4.88% incidence).\n\nTherefore, the numerical adverse event rates directly substantiate that skin infection was in fact the most frequent adverse event experienced.\n\nThe statement can be directly entailed based on the adverse event data provided showing skin infection to have the highest reported incidence.\n\nThe answer is entailment, as the \"most common\" claim is supported by the trial's quantiative adverse event results."}
{"id": "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2", "result": " Contradiction\n\nThe adverse events section reports:\n\nFebrile Neutropenia * 3/56 (5.36%)\n\nThe statement claims Febrile Neutropenia was the most common adverse event, affecting most patients in the trial.\n\nHowever, Febrile Neutropenia only affected 3 out of 56 patients (5.36%). All other adverse events affected only 1 patient each (1.79% incidence).\n\nWhile Febrile Neutropenia had the highest reported incidence, it cannot be said to have affected \"most patients\" since it only represented 3 out of 56 total patients.\n\nTherefore, the numerical adverse event rates do not directly substantiate that Febrile Neutropenia affected most patients as claimed in the statement.\n\nThe answer is contradiction, because while it had the highest rate, Febrile Neutropenia did not affect a majority or \"most\" of the trial patients according to the event frequency data provided."}
{"id": "c09fa61c-967a-40ae-96b0-c87b7cde237b", "result": " Entailment\n\nThe adverse events sections report adverse event rates as follows:\n\n- Anaemia * 4/100 (4.00%) \n- Febrile neutropenia * 3/100 (3.00%)\n- Febrile neutropenia * 3/152 (1.97%)\n\nAll other adverse events affected 1 patient or less, corresponding to rates of 1% or less.\n\nThe statement claims \"None of the individual Aes recorded in the primary trial affect more than 10% of the population.\"\n\nReviewing the reported adverse event rates, all are 10% or lower. \n\nThe highest rate is 4.00% for Anaemia in Adverse Events 1.\n\nTherefore, the numerical adverse event frequency data directly supports and entails the statement, as none exceeded the 10% threshold as stated.\n\nThe answer is entailment, because the quantitative adverse event results substantiate the rate cut-off specified in the statement."}
{"id": "4309860d-042d-45a4-8a0a-a9fdd075247a", "result": "  Contradiction\n\nThe intervention section states:\n\nINTERVENTION 1: \nNKTR-102\nIn Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.\n\nThis explicitly mentions Group A receives NKTR-102 administered via IV infusion.\n\nThe statement claims \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\".\n\nHowever, Group A defined in Intervention 1 clearly receives NKTR-102 via IV infusion, contradictory to the statement.\n\nTherefore, the intervention description directly contradicts the statement, as it specifies IV NKTR-102 infusion for one of the cohorts.\n\nThe answer is contradiction, because the trial details provided show IV NKTR-102 is administered to one group/cohort."}
{"id": "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85", "result": " Contradiction\n\nThe primary trial results measured and reported:\n\n- Overall Response (Complete Response, Partial Response or Stable Disease) of Participants \n\nThe secondary trial results measured and reported:\n\n- Percentage of Participants With Pathological Complete Response in Breast and Axilla\n\nThe statement claims the primary and secondary trials use identical outcome measurements.\n\nHowever, the outcomes measured are different between the two trials - overall response versus pathological complete response.\n\nTherefore, the statement that the trials use identical measurements cannot be directly entailed based on the results data which shows different metrics were assessed.\n\nThe answer is contradiction, as the results provided do not support the trials using the exact same outcome measurements as specified in the statement."}
{"id": "59cd7909-00c3-4c23-9a08-a42dbc8eabdd", "result": "  Entailment\n\nThe intervention section states:\n\n- Each treatment cycle is 28 days\n- Participants will be treated until disease progression \n\nThe statement claims: \n\n- Participants will not receive the intervention for a set number of cycles\n- The cycles will continue until disease progression\n\nThe details provided directly match what is stated - treatment continues in cycles until disease progression, rather than being administered for a predefined number of cycles.\n\nTherefore, the intervention regimen description substantiates and directly entails the details laid out in the statement.\n\nThe answer is entailment, as the trial schema outlined in the statement is precisely what is specified in the intervention plan provided."}
{"id": "e6a4e9a6-56b8-4a30-9743-eb02688c090f", "result": " Entailment\n\nThe eligibility criteria state inclusion of:\n\n- Node-positive: T1-3, N1-2, M0\n- Node-negative AND tumor >2cm or tumor >1cm and negative receptors or Grade 2-3 tumor etc. \n\nThe statement mentions two specific cases:\n\n1) Node positive T2 N2 M0 adenocarcinoma - this fits criteria of T1-3, N1-2, M0\n\n2) Node negative adenocarcinoma with 1.5cm tumor - this fits criteria of tumor >1cm \n\nBoth cases listed in the statement are explicitly accommodated under the inclusion criteria mentioned. \n\nTherefore, the eligibility details provided directly substantiate and entail the specific cases of eligibility listed in the statement.\n\nThe answer is entailment, as the patient characteristics specified align precisely with what is allowed under the trial criteria."}
{"id": "82a3e542-f784-44d7-90f6-34d7e969283c", "result": "  Entailment\n\nThe intervention section states participants received:\n\n- Avastin (Bevacizumab) 15 mg/kg IV every three weeks \n\n- As well as continuing with hormonal therapy they previously were taking\n\nThe statement claims:\n\n- The primary trial participants receive more than one type of medication during the study\n\nThe intervention plan explicitly specifies participants receive both Avastin and hormonal therapy. \n\nThis directly matches the statement, as receiving two types of medications (Avastin and hormones) substantiates the claim of receiving more than one medication.\n\nTherefore, the trial intervention details precisely entail the scope asserted in the statement.\n\nThe answer is entailment, as the statement is directly supported by the primary trial providing two medications to participants."}
{"id": "fb360514-14be-45ab-8b74-ea5a7eb181d7", "result": " Entailment\n\nThe primary trial adverse events section reports:\nTotal: 0/23 (0.00%) \n\nThe secondary trial adverse events sections report:\nTotal: 0/655 (0.00%)\nTotal: 0/580 (0.00%)\n\nBoth trials explicitly report a total of 0 adverse events out of the participants analyzed.\n\nThe statement claims \"the primary trial and the secondary trial do not report adverse events\".\n\nSince both trials show 0 adverse events occurred, this directly substantiates that adverse events were in fact not reported.\n\nTherefore, the adverse event results precisely entail the scope asserted in the statement, which is that the trials did not record any adverse events.\n\nThe answer is entailment, because the quantitative adverse event frequencies provided validate the statement regarding no adverse events being reported."}
{"id": "7137dec6-5c98-4156-8035-7bbaaf0b649d", "result": " Contradiction\n\nThe eligibility criteria specify:\n\n- Inclusion criteria: ECOG score of 0 or 1\n- No mention of ECOG score < 2 in exclusion criteria\n\nThe statement claims an ECOG score < 2 is necessary for eligibility. \n\nHowever, the criteria only lists 0 or 1 as includable scores. An ECOG of 2 is not discussed.\n\nTherefore, while an ECOG < 2 would include scores of 0 and 1, the criteria do not directly substantiate that a score of 2 would also be eligible as implied in the statement. \n\nThe answer is contradiction, as the exact ECOG threshold is 0 or 1 per the provided eligibility details, not < 2 as stated."}
{"id": "015dd869-db90-45a9-a951-9dc7dc2b2e01", "result": "  Contradiction \n\nThe eligibility criteria mentions the following:\n\nInclusion: \n- Must have received prior chemotherapy with Taxol or Taxotere\n- Less than 3 different chemo for metastatic disease  \n- Prior hormonal/radiation therapy\n- Measurable disease\n- Able to care for self\n\nExclusion:\n- Pregnant/breastfeeding  \n- Cancer spread to brain\n- Prior Gemcitabine or Pemetrexed\n- Unable to take folic acid/B12\n- Other cancer in last 5 years\n\nThe statement claims patients with brain tumor or colon cancer are eligible.\n\nHowever, the criteria specifically excludes cancer spread to brain. And it does not include colon cancer diagnosis under inclusion.\n\nTherefore, the eligibility details do not support patients with brain tumor or colon cancer being eligible, which contradicts the statement.\n\nThe answer is contradiction, as the provided criteria rules out these patient characteristics."}
{"id": "3a4003f6-ff1c-43d8-be48-f767266b2cf5", "result": "  Entailment\n\nThe primary trial eligibility criteria includes/excludes multiple criteria that are different than those specified in the secondary trial:\n\n- Primary trial allows any HER2 disease status but secondary requires HER2 overexpression  \n- Primary allows advanced/metastatic disease of any ER/PR status but secondary doesn't specify\n- Primary has criteria on prior therapies, organ function tests etc not mentioned in secondary\n- Secondary requires prior whole brain radiotherapy/SRS but primary doesn't specify\n- Secondary excludes pregnancy/lactation and conditions affecting oral absorption but primary doesn't\n\nThe statement claims the inclusion/exclusion conditions are not the same between the primary and secondary trial. \n\nComparing the two sets of criteria shows they do in fact differ on several criteria between the two trials.\n\nTherefore, the provided eligibility details directly entail and substantiate the scope described in the statement, that the conditions are not identical across the primary and secondary trial.\n\nThe answer is entailment, as the criteria show the trials do not have the exact same inclusion/exclusion rules."}
{"id": "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7", "result": " Entailment\n\nThe results provide:\n\n- Arm 1 (Paclitaxel/Bevacizumab/Everolimus): Median PFS 9.1 months, CI 6.8-10.8 months  \n- Arm 2 (Paclitaxel/Bevacizumab/Placebo): Median PFS 7.1 months, CI 5.6-10.8 months\n\nThe statement claims: \n\n- At least 2 participants, one from each cohort, had PFS of 10.8 months\n\nThe confidence intervals reported for both arms extend up to 10.8 months. \n\nTherefore, it can be directly inferred based on the numbers that at least one participant in each arm likely had a PFS of 10.8 months, as their upper confidence limit reaches that threshold.\n\nThe results provided precisely substantiate the scope outlined in the statement.\n\nThe answer is entailment, as the PFS confidence intervals reported validate what is asserted."}
{"id": "f3cb9150-32c6-4877-9a87-4fac45a24948", "result": "  Contradiction\n\nThe primary trial adverse events show:\nTotal: 0/34 (0.00%)\n\nThe secondary trial adverse events show:\n\nCohort 1:\nTotal: 6/62 (9.68%)\nMusculoskeletal * 1/62 (1.61%) \n\nCohort 2:  \nTotal: 1/64 (1.56%)\nMusculoskeletal * 0/64 (0.00%)\n\nThe statement claims all musculoskeletal AEs occurred in cohort 2 of the secondary trial.\n\nHowever, the results provided show 1 musculoskeletal AE occurred in cohort 1, not cohort 2 of the secondary trial.\n\nTherefore, the adverse event frequencies contradict the specification in the statement that all musculoskeletal AEs were only in cohort 2.\n\nThe answer is contradiction, as the reported data does not validate what is asserted in the statement."}
{"id": "9d8b26d6-d574-4717-88b6-77458bc683f3", "result": " Contradiction\n\nThe primary trial adverse events reported:\n\nTotal: 5/55 (9.09%) \nInfection 2/55 (3.64%)\nPain * 1/55 (1.82%) \nMuscle Weakness * 1/55 (1.82%)\nDyspnea 1/55 (1.82%)\n\nThe statement claims syncope was the most common AE.\n\nHowever, syncope is not listed as an adverse event in the reported data table. \n\nInfection at a frequency of 2/55 (3.64%) is shown to be the most common based on the numbers provided.\n\nTherefore, the adverse event frequencies directly contradict the assertion that syncope was the most frequent, as it is not even noted in the results.\n\nThe answer is contradiction, because the reported adverse event data does not substantiate syncope as the most common as specified in the statement."}
{"id": "51be7c95-8da4-419c-950c-91ebdd2c3fe5", "result": " Contradiction\n\nThe primary trial intervention details:\n\n- Intervention 1: BKM120 and Paclitaxel  \n- Intervention 2: Placebo and Paclitaxel\n\nThe secondary trial intervention details:\n\n- Intervention 1: Active Breathing Coordinator \n\nThe statement claims patients in the primary trial receive higher doses of BKM120 than the secondary trial.\n\nHowever, the secondary trial intervention does not involve administration of BKM120 at all. \n\nTherefore, the interventions provided do not substantiate making a direct dosage comparison of BKM120 between the two trials, since it is only used in the primary trial. \n\nThe answer is contradiction, as the information given does not allow validating the dosage relationship asserted in the statement."}
{"id": "07042b0f-d422-49c3-8d53-81319927a4b3", "result": "  Entailment\n\nThe primary trial eligibility criteria specifies:\n\n- Inclusion: histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition\n\nThe secondary trial eligibility criteria does not specify any cancer stage, only:\n\n- Inclusion: Patients with metastatic or advanced solid tumors\n- Women with histologically or cytologically confirmed triple negative breast carcinoma  \n- Patients with histologically or cytologically confirmed Pancreatic adenocarcinoma\n- Patients with histologically or cytologically confirmed NSCLC\n\nThe statement claims:\n\n- Primary trial requires stage 2 or 3 breast cancer\n- Secondary trial does not specify any required cancer stage\n\nComparing the inclusion criteria directly confirms the primary trial mandates stage 2 or 3 breast cancer, whereas the secondary trial does not outline a specific cancer stage must be present.\n\nTherefore, the eligibility details provided precisely entail and validate the scope described in the statement. \n\nThe answer is entailment, as the criteria substantiate what is asserted."}
{"id": "32361e21-ee57-4c34-9390-833ba5048a10", "result": "  Contradiction \n\nThe primary trial intervention details:\n\n- INTERVENTION 1: Fulvestrant + Everolimus\n- Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule\n- Everolimus was administered initially at a dose of 5 mg daily and then increased to 10 mg PO daily\n\nThe statement claims:\n\n- Fulvestrant was administered intramuscularly to the deltoid \n- Everolimus was administered orally\n\nHowever, the intervention provided specifies:\n\n- Fulvestrant administered to gluteus maximus intramuscularly  \n- Everolimus administered orally\n\nThe administration sites contradict what is stated in the statement. \n\nTherefore, the intervention details directly contradict the administration routes asserted in the statement.\n\nThe answer is contradiction, as the information given does not validate the administration sites outlined."}
{"id": "88668508-dfd4-4a39-91cd-cf1654a6dfc4", "result": " Contradiction\n\nThe primary trial results reported:\n\n- Outcome Measurement: Local Control Using Ipsilateral Breast Tumor Recurrence Rates \n\n- Arm 1 Title: Accelerated Partial Breast Brachytherapy\n- Arm 1 Description: Details of brachytherapy treatment  \n- Arm 1 Participants Analyzed: 151\n- Measure Type: Number  \n- Unit of Measure: percentage of participants .7\n\nThe statement claims the trial reports the proportion of patients experiencing dermatitis.\n\nHowever, the results provided report local control rates and do not mention dermatitis.\n\nSince the trial reports local control using IBTR rates and not dermatitis rates, this contradicts the assertion in the statement.\n\nTherefore, the trial results do not validate what is asserted in the statement. \n\nThe answer is contradiction, as the reported outcomes contradict the statement."}
{"id": "dca4c9f7-bb2a-4f73-b390-93b7ced87c73", "result": " Entailment\n\nThe primary trial results report:\n- Outcome measure: Number of participants with complete pathologic response \n- Arm 1 participants analyzed: 27\n- Measure type: Number\n- Unit of measure: Participants 13\n\nThe secondary trial results report:  \n- Outcome measure: Change in Masood score\n- Arm 1 participants analyzed: 84 \n- Measure type: Mean\n- Unit of measure: Units on a scale -1.1(1.9)\n\nThe statement claims the results from the two trials are non-comparable.\n\nComparing the outcome measures, measurement types, units of measurement and scales reported in the two trials shows they are clearly measuring different outcomes using different methodologies.\n\nTherefore, the results provided directly validate and substantiate that the trial results are non-comparable, as asserted in the statement.\n\nThe trial details precisely entail the scope described in the statement. \n\nThe answer is entailment, as the results support the statement."}
{"id": "e7604382-09cd-43b4-998f-a51b33f25c5a", "result": "  Contradiction\n\nThe primary trial intervention details:\n\n- INTERVENTION 1: Intraductal administration of dextrose or dextrose with PLD \n\nThe secondary trial intervention details: \n\n- INTERVENTION 1: Cetuximab given IV\n- INTERVENTION 2: Cetuximab + carboplatin given to patients from Arm 1\n\nThe statement claims the primary and secondary trial participants do not receive any medication orally.\n\nHowever, the intervention details provided do not specify if any medication was given orally or not. They only describe IV or intraductal administration.\n\nSince the given intervention information does not rule out oral administration, it does not substantiate the conclusive statement that no medication was given orally. \n\nTherefore, the intervention details directly contradict making the definitive assertion in the statement.\n\nThe answer is contradiction, as the information provided does not validate the absolute claim."}
{"id": "75affd49-4905-4d43-9a5c-ef795281bac4", "result": " Contradiction\n\nThe primary trial results reported:\n\n- Outcome Measurement: Overall Response Rate (ORR), the percentage of patients who experience an objective benefit from treatment \n\nArm A Results:\n- Participants analyzed: 42\n- Measure type: Number  \n- Unit of measure: percentage of patients 28 (16 to 42)\n\nArm B Results:  \n- Participants analyzed: 44\n- Measure type: Number\n- Unit of measure: percentage of patients 31 (18 to 45) \n\nThe statement claims neither intervention resulted in an objective benefit for more than 40% of patients.\n\nHowever, the reported ORR for Arm A is 28% (with confidence interval extending above 40%) and for Arm B is 31% (with confidence interval also extending above 40%).\n\nSince the confidence intervals provided validate the possibility of over 40% objective benefit for both arms, this contradicts the definitive statement made.\n\nTherefore, the trial results do not substantiate the claim in the statement.\n\nThe answer is contradiction, as the reported data conflicts with the assertion."}
{"id": "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65", "result": " Contradiction\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria:\n- Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\n\nExclusion Criteria:  \n- Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).\n\nThe statement claims eligibility requires:\n\n- Hormone receptor positive advanced breast cancer\n- Having received prior chemotherapy for this cancer\n\nHowever, the exclusion criteria explicitly mentions patients cannot have received \"Previous treatment for advanced breast cancer\".\n\nSince prior chemotherapy for advanced breast cancer is excluded, this directly contradicts requiring it for eligibility as stated in the statement.  \n\nTherefore, the eligibility details provided do not validate or substantiate what is asserted in the statement.\n\nThe answer is contradiction, as the criteria conflicts with the statement."}
{"id": "8c6314f7-34f5-42a7-ba66-b95d050a6315", "result": " Contradiction\n\nThe primary trial results reported:\n\n- Outcome Measurement: Progression Free Survival (PFS)\n- Arm 1 Participants Analyzed: 211 \n- Arm 1 PFS Median: 8.4 months (7.0 to 9.9)\n\n- Arm 2 Participants Analyzed: 211\n- Arm 2 PFS Median: 8.5 months (6.9 to 11.5)\n\nThe statement claims the shortest PFS in cohort 1 was 1.4 months below average. \n\nHowever, the results reported PFS as medians with confidence intervals, not averages. There is no information provided about specific individual PFS durations.\n\nSince the results do not include data to validate the claim of any patient being 1.4 months below average, this contradicts the statement.\n\nTherefore, the trial results do not substantiate the assertion made in the statement.\n\nThe answer is contradiction, as the reported outcomes conflict with the statement."}
{"id": "f114846e-79d8-4712-add0-bb34b65d418f", "result": " Contradiction\n\nThe primary trial results reported:\n\n- Outcome Measurement: Patients Event-free at 12 Months \n- Arm 1 Participants Analyzed: 6\n- Arm 1 Measure Type: Number  \n- Arm 1 Unit of Measure: Participants 6\n\n- Arm 2 Participants Analyzed: 7  \n- Arm 2 Measure Type: Number\n- Arm 2 Unit of Measure: Participants 7\n\nThe statement claims:\n\n- 6 recorded deaths in cohort 1 \n- 7 recorded deaths in cohort 2\n\nHowever, the results reported the number of event-free patients at 12 months, not the number of deaths. \n\nSince no data on deaths was provided in the results, this contradicts claiming specific death counts.\n\nTherefore, the trial results do not substantiate or validate the statement about recorded death numbers.\n\nThe answer is contradiction, as the outcomes reported conflict with the statement."}
{"id": "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe", "result": " Contradiction\n\nThe primary trial results reported:\n\n- Outcome Measurement: Change in Tumor Size (CTS) From Baseline to End of Cycle 2\n- Arm 1 Participants Analyzed: 17\n- Arm 1 Measure: Mean \n- Arm 1 Unit of Measure: log ratio of end of Cycle 2 to baseline -0.0 (0.08) \n\n- Arm 2 Participants Analyzed: 11\n- Arm 2 Measure: Mean\n- Arm 2 Unit of Measure: log ratio of end of Cycle 2 to baseline -0.1 (0.37)\n\nThe statement claims the trial reports changes in the number of lesions for patients.\n\nHowever, the results explicitly report measuring and analyzing change in tumor size, not number of lesions.\n\nSince the outcomes reported do not include data on number of lesions, this contradicts the statement.\n\nTherefore, the trial results do not validate or substantiate the assertion made regarding number of lesions.\n\nThe answer is contradiction, as the reported data conflicts with the statement."}
{"id": "b1d28450-fc7d-496a-9c7c-bf711b28f8e4", "result": " Contradiction\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria: \n- Adult Women aged 18 years or older\n- Confirmed HER2+ invasive breast cancer\n- Measurable or bone lesions only\n- Prior trastuzumab/chemotherapy allowed if discontinued >12 months ago\n- Prior endocrine therapy allowed if discontinued at randomization\n\nExclusion Criteria:\n- Pregnant patients\n\nThe statement claims all pregnant patients accepted into the trial have undergone prior endocrine therapy.\n\nHowever, the eligibility explicitly excludes pregnant patients. \n\nSince pregnant patients are not eligible for the trial, it contradicts to claim they were accepted and had a particular prior treatment.\n\nTherefore, the eligibility details directly contradict the assertion made in the statement regarding pregnant patients.\n\nThe answer is contradiction, as the criteria conflicts with the statement."}
{"id": "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3", "result": " Contradiction\n\nThe primary trial adverse events section reports:\n\n- Total adverse events: 2/30 (6.67%)\n- Dry eyes: 1/30 (3.33%) \n- Diarrhea: 1/30 (3.33%)\n\nThe statement claims no cardiac or neural adverse events were recorded.\n\nHowever, the adverse events reported only include dry eyes and diarrhea. No information is provided about cardiac or neural adverse events specifically. \n\nSince the adverse events listing does not rule out or validate the lack of cardiac/neural adverse events, it does not substantiate the definitive claim made in the statement. \n\nThe adverse events details directly contradict making an absolute assertion without sufficient supportive data.\n\nTherefore, the answer is contradiction - the information given conflicts with the definitive statement presented.\n\nThe primary trial adverse events section does not entail or validate the statement made regarding cardiac/neural adverse events."}
{"id": "a805f174-2707-4302-a195-05153ea8523e", "result": " Entailment\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria:\n- Metastatic breast cancer (Stage IV)  \n- Female\n- Age 18 years\n\nExclusion Criteria: \n- Women with Stage I-III breast cancer\n\nThe statement claims only adults can take part in the primary trial.\n\nThe inclusion criterion of requiring a minimum age of 18 years directly validates that only adults are eligible for the trial, as defined by the statement.\n\nNo aspects of the provided eligibility details contradict this.\n\nTherefore, the eligibility criteria precisely entail and substantiate the scope described in the statement regarding adult participants.\n\nThe answer is entailment, as the criteria clearly support and validate the statement."}
{"id": "e4aeb013-7713-4b73-acbd-f8379cc6a494", "result": " Entailment\n\nThe primary trial adverse events reported:\n\nCohort 1:\n- Total adverse events: 5/101 (4.95%) \n- Slipped disk: 0/101 (0.00%)\n\nCohort 2:\n- Total adverse events: 9/98 (9.18%)\n- Slipped disk: 1/98 (1.02%)\n\nThe statement claims there was a higher percentage of patients with slipped disks in cohort 2 than cohort 1.\n\nCohort 1 reports 0% patients with slipped disk, while cohort 2 reports 1.02%.\n\nThe adverse event details precisely validate what is stated, by reporting a higher percentage (1.02% vs 0%) of slipped disk events in cohort 2 compared to cohort 1. \n\nTherefore, the trial information directly entails and substantiates the scope described in the statement.\n\nThe answer is entailment, as the numbers provided support the claim."}
{"id": "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3", "result": " Contradiction\n\nThe primary trial results reported:\n\n- Outcome Measurement: Centrally Assessed Progression Free Survival (PFS) \n- Arm 1 Participants Analyzed: 307\n- Arm 1 PFS Mean: 8.8 months (7.8 to 9.8)\n\n- Arm 2 Participants Analyzed: 314 \n- Arm 2 PFS Mean: 6.6 months (5.9 to 7.4)\n\nThe statement claims:\n\n- All patients in cohort 1 had a PFS over 7 months\n- Highest PFS was just under 10 months\n\nHowever, the results reported PFS as means with 95% confidence intervals, not individual patient data. \n\nSince the exact individual PFS durations are not provided, the results do not validate that all patients were over 7 months or the highest was under 10 months.\n\nTherefore, the trial information does not substantiate the definitive claims made in the statement.\n\nThe answer is contradiction, as the reported data conflicts with the statement."}
{"id": "2729a321-709b-4392-9604-dd7237bedb17", "result": "  Entailment \n\nThe primary trial results reported:\n\n- Outcome Measurement: Disease-free Survival at 5 years\n- Arm 1 Participants Analyzed: 1610\n- Arm 1 Disease-free Survival: 80.1% (78.0 to 82.0%)\n\n- Arm 2 Participants Analyzed: 1618\n- Arm 2 Disease-free Survival: 82.2% (80.2 to 84.0%)\n\nThe statement claims the majority of participants in cohorts 1 and 2 achieved Disease-free Survival for 5 years.\n\nBoth arms reported Disease-free Survival rates over 80%, with confidence intervals entirely above 50%.\n\nThe results directly validate what is stated, by reporting Disease-free Survival rates above the 50% majority level for both cohorts.\n\nTherefore, the trial information precisely entails and supports the claim made in the statement.\n\nThe answer is entailment, as the numbers quantitatively substantiate the statement."}
{"id": "8e9611fc-89f8-44cb-af09-8d71a13ca082", "result": " Entailment\n\nThe primary trial intervention section reports:\n\nIntervention 1: \n- Group A receives NKTR-102 at 145 mg/m2 q21d\n\nIntervention 2:  \n- Group B receives Treatment of Physician's Choice (TPC) consisting of single agent IV chemo from a list of 7 options\n\nThe statement claims cohorts 1 and 2 do not receive the same intervention.\n\nIntervention 1 clearly specifies NKTR-102 only for Group A. \nIntervention 2 specifies TPC including different single agent chemo options for Group B.\n\nThe intervention details precisely validate that the two groups do not receive the same treatments, as stated.\n\nTherefore, the trial information directly entails and supports what is described in the statement regarding different interventions between cohorts.\n\nThe answer is entailment, as the scope outlined is unambiguously substantiated by the intervention protocols provided."}
{"id": "b9491012-49ba-4eb1-8230-1966f54ea012", "result": " Entailment\n\nThe primary trial eligibility criteria specifies:\n\nDisease Characteristics:\n- Histologically confirmed breast cancer with radiographically confirmed brain metastases  \n- Extracranial metastases allowed\n\nThe statement claims patients with extracranial metastases can be eligible for the primary trial. \n\nThe eligibility explicitly includes \"Extracranial metastases allowed\" under the disease characteristics section.\n\nNo other criteria contradict this inclusion of extracranial disease.\n\nTherefore, the eligibility details precisely validate and substantiate what is described in the statement regarding eligibility of patients with extracranial metastases.\n\nThe answer is entailment, as the criteria clearly and directly support the claim made."}
{"id": "62e449ad-16b3-479d-94a5-ffc435b5e99c", "result": " Contradiction\n\nThe primary trial eligibility criteria specifies inclusion and exclusion details:\n\nInclusion Criteria: \n- Prior chemo with paclitaxel or docetaxel\n- <3 prior chemo for metastatic disease  \n- Prior hormonal or radiation therapy\n- Measurable disease\n- Able to care for self\n\nExclusion Criteria:\n- Pregnant or breastfeeding\n- Cancer spread to brain  \n- Prior gemcitabine or pemetrexed  \n- Unable to take folic acid or B12\n- Prior cancer in last 5 years\n\nThe statement claims patients with a malignant brain tumour diagnosis are excluded. \n\nHowever, the criteria only specifies exclusion of cancer spread to the brain, not a primary brain tumour diagnosis.\n\nAs no mention is made of excluding primary brain cancers, the eligibility details do not validate or substantiate excluding patients solely based on a brain tumour diagnosis.\n\nTherefore, the answer is contradiction - the information provided conflicts with the statement."}
{"id": "565d7982-aa9a-4c01-987c-1d67bc9c212d", "result": " Contradiction\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria:  \n- Biopsy-diagnosed metastatic breast cancer\n- Performance status 0-2\n- Specified lab values maintained\n- Informed consent\n\nExclusion Criteria:\n- Concurrent cancers   \n- Infection/fever\n- CNS metastases\n- Cardiac disease\n- Ulcer\n- Neuropathy\n- Pregnancy\n- Allergies\n- Bone marrow suppression \n- Renal disease\n- Concurrent pyrimidine/flucytosine therapy\n- Current infection\n\nThe statement claims ongoing flucytosine treatments are necessary, starting at least 6 months before entry.\n\nHowever, the criteria explicitly excludes patients being treated with flucytosine.\n\nAs flucytosine is an exclusion, the eligibility cannot validate or require its ongoing use as stated. \n\nTherefore, the criteria directly contradicts the claims made in the statement regarding flucytosine therapy eligibility.\n\nThe answer is contradiction, as the information conflicts with the statement."}
{"id": "7271e0db-bb82-423f-ad95-5ffa84fab97e", "result": " Contradiction\n\nThe primary trial adverse events reported:\n- Urosepsis: 2/12 (16.67%) \n\nThe secondary trial adverse events reported:\n- Adverse Events 1: No urosepsis cases reported\n- Adverse Events 2: No urosepsis cases reported\n\nThe statement claims there are more cases of urosepsis in the primary trial than the secondary trial.\n\nHowever, the secondary trial adverse events do not report any cases of urosepsis.\n\nWhile the primary trial reports 2 cases, comparing it to zero cases in the secondary trial conflicts with stating there are more in the primary trial.\n\nTherefore, the adverse event details do not validate the statement, since no urosepsis cases are noted in the secondary trial reports.\n\nThe answer is contradiction, as the information provided conflicts with the definitive claim made."}
{"id": "6402e13a-7cfb-4774-b7f9-80ecb79fda2a", "result": " Contradiction\n\nThe primary trial intervention specifies:\n- Positron Emission Mammography scans \n\nThe secondary trial intervention specifies:\n- Exemestane 25mg oral daily for 5 years\n- Anastrozole 1mg oral daily for 5 years\n\nThe statement claims:\n- Primary trial does not administer oral medications\n- Secondary trial only provides oral treatments\n\nHowever, the primary trial does not mention any oral or other medications. \n\nAnd the secondary trial clearly describes oral aromatase inhibitors as the interventions.\n\nAs the primary trial information does not validate the negative claim about oral medications, and the secondary trial positively describes oral treatments, the statement is contradicted.\n\nTherefore, the answer is contradiction - the trial intervention details conflict with the assertions made in the statement."}
{"id": "734423d5-4b47-4448-ab98-811015d626f0", "result": " Entailment\n\nThe primary trial adverse events reported:\n\nCohort 1: \n- Total events: 3/39 (7.69%)\n- Neutropenia: 1/39 (2.56%) \n\nCohort 2:\n- Total events: 3/21 (14.29%)  \n- Neutropenia: 1/21 (4.76%)\n\nThe statement claims there were multiple patients who suffered Neutropenia in both cohorts.\n\nBoth cohorts reported Neutropenia occurred in 1 patient for each cohort.\n\nThe adverse event details precisely validate what is stated, by reporting Neutropenia cases in both cohorts.\n\nTherefore, the trial information directly entails and substantiates the claim made in the statement regarding Neutropenia occurring in multiple patients across cohorts.\n\nThe answer is entailment, as the numbers provided unambiguously support the statement."}
{"id": "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd", "result": " Contradiction\n\nThe primary trial intervention specifies:\n- Arm A: 1 mg anastrozole pill per day + flaxseed\n- Arm B: Flaxseed only (no anastrozole)\n\nThe secondary trial intervention specifies: \n- Cohort A: 1 mg anastrozole orally once daily + AZD0530\n\nThe statement claims:\n- Primary trial all get anastrozole pills\n- Secondary trial none get anastrozole\n\nHowever, the primary trial clearly shows Arm B does not receive anastrozole. \n\nAnd the secondary trial explicitly lists anastrozole as part of the Cohort A intervention.\n\nAs the primary trial does not validate all participants receiving anastrozole pills, and the secondary trial positively describes anastrozole use, the statement is contradicted.  \n\nTherefore, the answer is contradiction - the trial intervention details conflict with the assertions made."}
{"id": "32ed503c-1cfd-44f6-b8bb-23d9d175d73d", "result": " Entailment\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria:\n- Pathologically confirmed breast cancer undergoing neoadjuvant therapy  \n- Locally advanced but not stage IV tumor \u22652cm\n- Able to undergo PET scan and lie still for 1.5 hours\n\nExclusion Criteria: \n- Prior breast cancer treatment\n- Uncontrolled illness\n- Medically unstable  \n- Unable to undergo PET scan\n\nThe statement claims patients must be able to undergo a PET scan to participate.\n\nThe inclusion criteria explicitly requires the ability to undergo a PET scan. No exclusion contradicts this.\n\nTherefore, the eligibility details directly validate and substantiate what is described in the statement regarding PET scan capacity as a requirement.\n\nThe answer is entailment, as the criteria precisely entails the claim made in the statement."}
{"id": "175044aa-72b1-405d-8506-30002f5098e4", "result": " Contradiction\n\nThe primary trial adverse events section reports:\n\nAdverse Events 1:  \n- Total: 0\n\nThe statement claims the adverse events section describes the number of patients suffering from hypotension, hemorrhage and bradycardia.\n\nHowever, the adverse events section only reports a total of 0 events, without specifying any individual adverse events.\n\nAs the provided information does not include details on hypotension, hemorrhage or bradycardia occurrence, it cannot validate or substantiate the claim made in the statement.  \n\nTherefore, the answer is contradiction - the trial adverse events details do not support the assertions regarding specific adverse events mentioned. No individual adverse events are described or quantified.\n\nSo the information conflicts with what is stated about the contents of the adverse events section."}
{"id": "045ad91e-44fa-42cc-ac22-a7aab26a9009", "result": "  Contradiction \n\nThe primary trial intervention specifies:\n\nIntervention 1:\n- Avastin (Bevacizumab) 15 mg/kg IV every 3 weeks\n- Continuing previous hormonal therapy\n\nThe statement claims the intervention includes:\n\n- Avastin \n- Bevacizumab\n- Radiotherapy\n\nHowever, the intervention details only describe Avastin and hormonal therapy, without mentioning Bevacizumab or radiotherapy.\n\nAs the provided information does not validate administering Bevacizumab or radiotherapy as part of the intervention, it does not substantiate the full claim made in the statement.\n\nTherefore, the answer is contradiction - the trial intervention details do not fully support all elements stated regarding the intervention administered. \n\nIt directly contradicts inclusion of Bevacizumab and radiotherapy as no reference is made to those."}
{"id": "00822101-fa21-4a26-bf45-3b1f535da005", "result": "  Entailment\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria:\n- Signed consent \n- Age 18+\n- Histologically confirmed breast cancer\n- Progressed on 1 prior chemo \n- ECOG 0-1\n- Contraception for women\n- Life expectancy 3 months\n\nExclusion Criteria: \n- Hormone therapy only for metastatic disease\n- LVEF <50% with prior anthracycline  \n- >1 prior chemo for MBC\n- HER2-positive status\n- Unknown ER/PR status\n- Recent radiation/biologic/chemo\n- Prior anti-VEGF therapy\n- Untreated brain mets\n- Cardiac/vascular issues\n- Bleeding risks\n- Recent procedures  \n- Pregnancy/lactation\n- Other diseases risking participation\n\nThe statement claims a HER2-positive patient cannot participate.\n\nThe exclusion criteria explicitly excludes patients with HER2-positive status.\n\nTherefore, the eligibility details directly validate and substantiate what is described in the statement regarding HER2-positive patients being ineligible.\n\nThe answer is entailment, as the criteria precisely entails the claim made."}
{"id": "06f798d1-2956-4903-83e9-58a41fa425f7", "result": " Entailment\n\nThe primary trial adverse events reported:  \n- Adverse Events 1: Total 0/655 (0.00%)   \n- Adverse Events 2: Total 0/580 (0.00%)\n\nThe secondary trial adverse events reported:\n- Adverse Events 1: Total 0/15 (0.00%)\n- Adverse Events 2: Total 0/16 (0.00%)\n\nThe statement claims the primary and secondary trials do not record any cardiac or infection adverse events.\n\nBoth the primary and secondary trial adverse event sections report a total of 0 events for all cohorts, without specifying any individual adverse events. \n\nBy reporting no adverse events at all, this necessarily means they did not record any cardiac or infection events specifically.\n\nTherefore, the adverse event details precisely validate what is stated by substantiating that no adverse events of any type, including cardiac or infection, were recorded.\n\nThe answer is entailment, as recording a total of 0 events directly supports the statement that those specific adverse event types were not documented. The numbers provided unambiguously validate the claim."}
{"id": "8648c7df-582a-42a9-9330-414b2430ac56", "result": " Contradiction\n\nThe primary trial adverse events report:\n\nCohort 1:  \n- Total events: 340/1612 (21.09%)\n- Myocardial infarction: 6/1612 (0.37%)\n\nCohort 2:\n- Total events: 350/1623 (21.57%)\n\nThe statement claims:\n- No individual AE affects >100 patients \n- Total AEs <30 patients\n\nHowever, the adverse event details report:\n\n- Total AEs for Cohort 1 were 340 patients\n- Total AEs for Cohort 2 were 350 patients \n\nThis contradicts the claim of total AEs being <30 patients.\n\nAdditionally, while no individual AE affects >100, the total enrolled was over 1600 for each cohort.\n\nTherefore, the adverse event numbers do not validate or substantiate the statements made, and directly conflict with the patient totals reported. \n\nThe answer is contradiction, as the trial information provided contradicts the assertions."}
{"id": "89f610a7-9e81-43a4-8c1e-5503233b2be1", "result": " Entailment\n\nThe primary trial eligibility criteria specifies:\n\nInclusion Criteria:\n- Pathologically confirmed breast cancer with documented progressive disease\n- Stable brain mets allowed  \n- \u22651 prior chemo for MBC\n- Concomitant bisphosphonates allowed\n- Stable anticoagulation allowed\n- Measurable or evaluable disease\n- Core biopsy amenable or pulmonary only mets\n\nThe statement claims patients must have documented stable disease to participate. \n\nWhile the inclusion criteria does state \"progressive disease\" initially, it goes on to explicitly allow for patients with stable brain mets or stable anticoagulation.\n\nTherefore, the eligibility details directly validate and substantiate what is described in the statement regarding stable disease being permitted for participation.\n\nThe answer is entailment, as the criteria precisely entails the claim made in the statement about stable disease patients being eligible."}
{"id": "b0046821-ba27-4a90-8869-cb708b843aa4", "result": " Entailment\n\nThe primary trial interventions specify:\n\nIntervention 1: Arm A - Flaxseed & Anastrozole \nIntervention 2: Arm B - Flaxseed only\n\nThe secondary trial intervention specifies:\n\nIntervention 1: Cohort A - Anastrozole & AZD0530\n\nThe statement claims:\n\n- All primary trial participants receive flaxseed  \n- None in secondary trial receive flaxseed\n\nThe primary trial interventions explicitly include flaxseed for both arms.\n\nThe secondary trial intervention does not mention flaxseed at all.\n\nTherefore, the intervention details precisely validate and substantiate the claims made in the statement regarding flaxseed administration between the two trials.\n\nThe answer is entailment, as the information provided unambiguously entails the statements about flaxseed use."}
{"id": "d1b217ae-76f3-4ba6-958e-5b2558703ba4", "result": " Entailment\n\nThe primary trial adverse events reported:\n\nCohort 1:\n- Total events: 1/35 (2.86%)  \n- Congestive heart failure: 1/35 (2.86%)\n\nCohort 2:  \n- Total events: 0/40 (0.00%)\n- Congestive heart failure: 0/40 (0.00%)\n\nThe statement claims:\n\n- Several CHF cases in cohort 1 \n- None in cohort 2\n\nThe adverse event details explicitly validate both parts of this statement:\n\n- 1 case of CHF reported in cohort 1\n- 0 cases reported in cohort 2\n\nTherefore, the numbers precisely substantiate that there were CHF cases in cohort 1 but none in cohort 2, as stated.\n\nThe answer is entailment, as the adverse event information provided unambiguously entails the assertions made."}
{"id": "8ddf8b88-6e06-4c71-9e28-45f73a637af0", "result": " Contradiction\n\nThe primary trial intervention specifies:\n\nIntervention 1: Positron Emission Mammography scans\n\nThe secondary trial interventions specify: \n\nIntervention 1: Exemestane orally daily\nIntervention 2: Anastrozole orally daily\n\nThe statement claims:\n\n- Primary trial gets oral and topical treatment\n- Secondary trial only oral treatment\n\nHowever, the primary trial details only describe imaging scans and does not mention any medication administration. \n\nThe secondary trials explicitly state oral drug administration.\n\nTherefore, the intervention information does not validate or substantiate the statement about topical treatment in the primary trial. \n\nThe details directly contradict the assertions regarding route of administration between the two trials.\n\nThe answer is contradiction, as the provided intervention data conflicts with the claims made."}
{"id": "0ea29bd5-20be-40ea-8ad7-705d283d1d48", "result": " Contradiction\n\nThe primary trial results reported disease-free survival rates as:\n\nCohort 1: \n- 80.1% (78.0 to 82.0) \n\nCohort 2:\n- 82.2% (80.2 to 84.0)\n\nThe statement claims the majority in cohorts 1 and 2 suffered recurrence/disease outcomes.\n\nHowever, the results explicitly state over 80% disease-free survival for both cohorts at 5 years.\n\nReporting >80% disease-free survival directly contradicts the assertion that the majority suffered recurrence/disease outcomes.\n\nTherefore, the result details do not validate or substantiate the statements made, and directly conflict with the disease-free rates provided.\n\nThe answer is contradiction, as the trial information contradicts the claims regarding outcome experience of the majority."}
{"id": "e147796d-2edd-42d1-ac53-300fb8bd5eb6", "result": " Contradiction\n\nThe primary trial intervention details specify:\n\nIntervention 1: Lapatinib 1500 mg orally daily\nIntervention 2: Placebo orally daily \n\nThe statement claims 80% of patients received placebo.\n\nHowever, the intervention sections do not provide any numbers or percentages to indicate what proportion of patients received each treatment. \n\nSimply describing two separate intervention arms without numeric allocation does not validate or substantiate an assertion about a specific percentage receiving one intervention over the other.\n\nTherefore, the intervention information given does not support the 80% figure stated for receiving placebo.\n\nThe answer is contradiction, as the trial details do not corroborate the percentage claimed in the statement. Numeric participant breakdown would be needed to entail such a claim.\n\nThe information provided conflicts with definitively stating an 80% rate for one intervention."}
{"id": "6b33b4ae-36f2-4a53-a954-6f246f6e023d", "result": "  Entailment \n\nThe eligibility criteria specify:\n\nInclusion Criteria:\n- Known and documented HER2-positive\n- Known and documented LVEF of at least 50 percent (%)\n\nThe statement asserts patients must have:\n\n- Known and documented HER2+ status\n- An LVEF of at least 50 percent (%)\n\nThese two criteria are explicitly listed under the inclusion criteria.\n\nTherefore, the eligibility details precisely validate and substantiate the criteria described in the statement for participation in the primary trial.\n\nThe answer is entailment as the provided trial information unambiguously entails the assertions made."}
{"id": "06fad978-1dc3-46f5-b45f-5ac6577f28b9", "result": " Contradiction\n\nThe primary trial specifies eligibility for:\n- Females with advanced breast cancer\n\nThe secondary trial specifies eligibility for:  \n- Postmenopausal women with hormone receptor positive advanced breast cancer\n\nThe statement claims patients must have:\n- Be female \n- Have confirmed advanced colon cancer\n\nHowever, the primary trial specifies breast cancer and the secondary specifies breast cancer. \n\nNeither mention colon cancer. \n\nAdditionally, the primary trial does not require postmenopausal status.\n\nTherefore, the eligibility criteria provided do not validate or substantiate the assertions made in the statement regarding cancer type and other requirements.\n\nThis contradicts the statement about patients needing advanced colon cancer for eligibility.\n\nThe answer is contradiction, as the trial details conflict with the claims in the statement."}
{"id": "878c09e7-3fd9-404e-921e-5b549e9578fb", "result": " Entailment\n\nThe primary trial results reported:\n\nCohort: Trastuzumab Emtansine  \n- Grade 1: 53/70 participants (75.7%)\n- Grade 2: 40/70 participants (57.1%) \n- Grade 3: 18/70 participants (25.7%)\n- Grade 4: 2/70 participants (2.9%)\n- Grade 5: 12/70 participants (17.1%)\n\nThe statement claims:\n- Most patients experienced Grade 1 AEs  \n- Least common was Grade 4\n\nThe results clearly show:\n\n- Grade 1 was the most frequently reported (75.7%)\n- Grade 4 was the least frequently reported (2.9%)\n\nTherefore, the adverse event severity numbers precisely validate and substantiate what is stated.\n\nThe answer is entailment, as the trial results unambiguously entail the assertions made in the statement."}
{"id": "3a0c517d-9b9a-4497-9675-50ff12cd02b7", "result": "  Entailment\n\nThe primary trial adverse events reported:\n\nCohort 1:\n- Left ventricular dysfunction: 2/219 (0.91%)\n- Abdominal pain: 1/219 (0.46%) \n\nThe statement asserts:\n\n- Cohort 1 had more cases of left ventricular dysfunction than abdominal pain\n\nThe numbers precisely validate this statement, showing:\n\n- 2 cases of left ventricular dysfunction \n- 1 case of abdominal pain\n\nTherefore, the adverse event frequencies unambiguously entail the direct comparison made in the statement between the two AEs.\n\nThe answer is entailment, as the trial information provided unambiguously substantiates the relative occurrence claims."}
{"id": "9abb10d7-496e-44fd-915d-d86aedf6c9b6", "result": " Contradiction\n\nThe eligibility criteria for the primary trial specify:\n\n- Known and documented HER2-positive \n- Known and documented LVEF of at least 50%\n\nThe statement asserts patients must have:\n\n- Known and documented TNBC status \n- LVEF of at least 50%\n\nHowever, the trial information explicitly requires HER2-positive status, not TNBC status. \n\nIt does not mention TNBC (triple negative breast cancer) at all in the eligibility.\n\nWhile LVEF of 50% is corroborated, the cancer subtype mentioned contradicts what is provided.\n\nTherefore, the eligibility details do not validate or substantiate having TNBC status as stated. \n\nThis directly conflicts with the criteria given in the primary trial information.\n\nThe answer is contradiction, as the trial information contradicts one part of the statement regarding cancer type required for participation."}
{"id": "8460a212-8054-4bd2-b4e6-af1d137a2f79", "result": "  Entailment\n\nThe primary trial results section reports:\n\n- Measure Type: Number  \n- Unit of Measure: percentage of participants 26 (13 to 44)\n\nThe secondary trial results section reports: \n\n- Measure Type: Number\n- Unit of Measure: proportion of nodes\n  - Proportion detected by Tc method: 0.86\n  - Proportion detected by ICG method: 0.95\n\nThe statement asserts the primary and secondary trials report results using different units of measure.\n\nThis is directly substantiated by the details provided, which show:\n\n- Primary reports in percentage \n- Secondary reports in proportion\n\nTherefore, the trials unambiguously report their results using different units as claimed in the statement.\n\nThe answer is entailment, as the trial information provided precisely validates the assertion made."}
{"id": "a3390ae6-d41d-4dc7-899e-de9534adfd6b", "result": " Contradiction\n\nThe primary trial intervention details:\n\nIntervention 1: \n- Lapatinib 1250 mg orally daily\n- Capecitabine 2000 mg/m^2 orally twice daily on days 1-14 of a 21 day cycle\n\nThe statement claims the Capecitabine dose is significantly higher than the Lapatinib dose.\n\nHowever, the doses are reported in different units:\n\n- Lapatinib in mg \n- Capecitabine in mg/m^2\n\nWithout a conversion between the units, there is no way to substantiate that one dose is significantly higher based on the information given. \n\nReporting doses in different units prevents a direct comparison of relative magnitudes.\n\nTherefore, the intervention details do not validate or support the assertion that the Capecitabine dose is significantly higher. \n\nThis conflicts with being able to definitively make that claim from the data provided.\n\nThe answer is contradiction, as the trial information does not allow substantiating the dose comparison in the statement."}
{"id": "17bbea92-8f92-41f3-9b9d-cf6e62cf6798", "result": " Entailment\n\nThe primary trial results report:\n\nCohort 1 (Neratinib 160 mg + Paclitaxel 80 mg/m2):\n- Dose Limiting Toxicity: 0/3 participants (0.0%) \n\nCohort 2 (Neratinib 240 mg + Paclitaxel 80 mg/m2):  \n- Dose Limiting Toxicity: 0/5 participants (0.0%)\n\nThe statement defines Dose Limiting Toxicity as:\n\n- The percentage of patients that suffer side effects serious enough to prevent an increase in dose/level of treatment\n\nThis precisely matches the outcome defined and results reported in the trial details.\n\nTherefore, the trial results unambiguously validate and substantiate what is described in the statement. \n\nThe answer is entailment, as the information provided precisely entails the assertions made."}
{"id": "794269ca-e7ec-4a65-ace5-b0f24a8cdc15", "result": "  Entailment \n\nThe primary trial results measure and report:\n\n- Outcome: Percentage of Participants With Objective Response\n- Unit of Measure: percentage of participants\n\nThe secondary trial results measure and report:\n\n- Outcome: Progression Free Survival \n- Unit of Measure: months\n\nThe statement asserts the primary trial measures percentage objective response while the secondary measures PFS.\n\nThis is directly validated by the outcomes and units of measure precisely reported in the trial sections.\n\nTherefore, the trial information provided unambiguously entails the differences in measured outcomes claimed in the statement.\n\nThe answer is entailment, as the details conclusively substantiate the distinction between measures stated."}
{"id": "4dfff980-6a2b-4f01-9194-6ec831d6fed7", "result": " Entailment\n\nThe primary trial adverse events reported:\n\n- Infection: 2/55 participants (3.64%)  \n- Pain: 1/55 participants (1.82%)\n- Muscle Weakness: 1/55 participants (1.82%)  \n- Dyspnea: 1/55 participants (1.82%)\n\nThe statement asserts:\n\n- Infections were the most common adverse events\n\nThis is directly validated by the adverse event frequencies provided:\n\n- Infections occurred in 2 participants \n- The other events each occurred in 1 participant\n\nTherefore, the numbers unambiguously substantiate infections as being more frequent than the other reported adverse events.\n\nThe answer is entailment, as the adverse event data explicitly validates the claim made in the statement about the most common event.\n\nThe trial information precisely entails the relative frequency relationship asserted."}
{"id": "dc4c57b0-8c75-494e-81b0-3528df85ebff", "result": " Contradiction\n\nThe primary trial results reported outcome as:\n- LDex Change measured in units of LDex \n\nThe secondary trial results reported outcome as:\n- Overall Survival of Patients measured in months\n\nThe statement claims neither trial records Overall Survival.\n\nHowever, the secondary trial explicitly reports measuring and recording Overall Survival in months.\n\nWhile the primary trial measures a different outcome, the secondary trial unambiguously measures Overall Survival as stated.\n\nTherefore, part of the statement is contradicted by the information provided.\n\nThe answer is contradiction, as the secondary trial results directly conflict with the claim that Overall Survival is not recorded.\n\nThe trial details do not fully validate or substantiate the statement regarding outcomes measured."}
{"id": "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c", "result": " Contradiction\n\nThe primary trial defines Objective Response as:\n\n- Complete response (CR) or partial response (PR) \n\nThe secondary trial does not provide a definition of Complete Response.\n\nThe statement asserts the trials use different definitions of Complete Response.\n\nHowever, only the primary trial defines Complete Response. The secondary trial information does not mention how Complete Response is defined.\n\nSo there is no evidence provided that the trials actually use different definitions of Complete Response as claimed. \n\nThe information given contradicts being able to validate this part of the statement.\n\nTherefore, while the outcome is the same, the statement about different Complete Response definitions is not substantiated and is contradicted by the lack of relevant details in the secondary trial results.\n\nThe answer is contradiction, as one component of the statement is directly refuted by the information provided."}
{"id": "251a20d8-2555-4929-9d01-c02311bdc93f", "result": " Entailment\n\nThe primary trial results report:\n\nCohort 1 (Fulvestrant and Dasatinib):\n- Number of participants with PD or death: 35/50\n\nCohort 2 (Fulvestrant only):\n- Number of participants with PD or death: 40/49 \n\nThe statement asserts a higher proportion of patients had PD or death in Cohort 2 compared to Cohort 1.\n\nThis is directly validated by the numerical results:\n\n- Cohort 1: 35/50 = 70%  \n- Cohort 2: 40/49 = 81.6%\n\nTherefore, the percentages unambiguously substantiate that a larger proportion of patients suffered the outcome in Cohort 2 versus Cohort 1, as claimed.\n\nThe answer is entailment, as the trial results precisely validate the comparative relationship stated."}
{"id": "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1", "result": " Entailment\n\nThe primary trial results measure and report:\n\n- Outcome: LDex Change \n- Unit of Measure: LDex\n\nThe secondary trial results measure and report:\n\n- Outcome: Overall Survival of Patients\n- Unit of Measure: months\n\nThe statement asserts the trials do not record the same metrics in their results sections.\n\nThis is directly validated by the trial details, which show:\n\n- Primary measures LDex change \n- Secondary measures overall survival\n\nThese are unambiguously different metrics as claimed.\n\nTherefore, the information provided precisely entails the statement, as it substantiates the primary and secondary trials do not record the same results measures.\n\nThe answer is entailment, as the details conclusively validate the distinction in metrics recorded between the two trials."}
{"id": "f0273b8c-460d-46fe-9c52-8ff4b08e439b", "result": " Entailment\n\nThe primary trial eligibility criteria specify:\n\n- Inclusion: Women >=18 years of age\n- Inclusion: Newly diagnosed, infiltrating HER2-negative or positive breast cancer  \n\nThe statement provides:\n\n- Eliane is a 56 year old woman\n- Elizabeth is a 32 year old woman\n\nBoth meet the inclusion criteria of:\n\n1) Being women \n2) Being >=18 years of age\n\nNo other details are provided about Eliane or Elizabeth's cancer status. \n\nHowever, the eligibility information does not specify an upper age limit.\n\nTherefore, based on the details given regarding their age and gender, both Eliane and Elizabeth could potentially meet the eligibility criteria to participate in the primary trial, as claimed in the statement.\n\nThe answer is entailment, as the trial eligibility details do not contradict that both women named could in principle be eligible as stated. The information provided validates the assertion made."}
{"id": "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8", "result": " Entailment\n\nThe primary trial eligibility criteria include:\n\n- Inclusion Criteria: Pathologically confirmed diagnosis of breast cancer with documented progressive disease. \n\nThe statement asserts that to participate in the primary trial, breast cancer patients must have documented progressive disease.\n\nThis is directly substantiated by the inclusion criteria listed, which explicitly require \"documented progressive disease\".\n\nThere is no conflicting information provided. The eligibility details precisely validate what is claimed in the statement.\n\nTherefore, the answer is entailment - the trial information unambiguously entails the assertion made about the requirement for progressive disease status.\n\nThe statement is precisely substantiated based on the numbers/details given regarding eligibility criteria."}
{"id": "c2217d42-e90c-4ffe-b084-e653b9ace4d5", "result": " Contradiction\n\nThe primary trial adverse events sections report:\n\n- Total adverse events in all cohorts as 0/655 (0.00%) \n- Total adverse events in all cohorts as 0/580 (0.00%)\n\nThe secondary trial adverse events sections report: \n\n- Total adverse events in all cohorts as 0/15 (0.00%)\n- Total adverse events in all cohorts as 0/16 (0.00%)\n\nBoth trials report a total of 0 adverse events occurring.\n\nThe statement claims the trials do not record cardiac/infection AEs but do record epilepsy AEs.\n\nHowever, the information provided contradicts this, as it shows:\n\n- No adverse events were recorded at all in either trial.\n\nTherefore, the trial details do not validate or substantiate the assertions made in the statement about specific adverse events recorded. \n\nThe answer is contradiction, as the statement is refuted by the adverse event data presented."}
{"id": "080da381-b5dd-46d3-99c4-18112da153c1", "result": " Contradiction\n\nThe primary trial adverse events section is blank/missing data. \n\nThe secondary trial adverse events reported are:\n\nCohort 1:  \n- Acute myocardial infarction: 0/199 (0.00%)\n- Cardiopulmonary failure: 1/199 (0.50%)  \n- Supraventricular tachycardia: 1/199 (0.50%)\n\nCohort 2:\n- Acute myocardial infarction: 1/36 (2.78%)\n- Cardiopulmonary failure: 0/36 (0.00%)\n- Supraventricular tachycardia: 1/36 (2.78%)\n\nThe statement compares data from the primary and secondary trials. \n\nHowever, the primary trial data is missing. There is no cohort 2 data from the primary trial to compare to.\n\nTherefore, the information provided does not validate or substantiate the comparative relationship between trials asserted in the statement. \n\nThe answer is contradiction, as the statement cannot be assessed due to lack of complete data as specified. The comparison described is not supported."}
{"id": "c100a7cd-e3a2-4901-a3e0-12336f769c7b", "result": " Contradiction\n\nThe primary trial adverse events reported:\n\n- Total adverse events: 16/48 (33.33%)\n- It does not report conjunctivitis separately\n\nThe secondary trial adverse events reported:\n\nCohort 1:\n- Conjunctivitis: 0/519 (0.00%) \n\nCohort 2:  \n- Conjunctivitis: 1/532 (0.19%)\n\nThe statement claims the secondary trial reported 1 case of conjunctivitis, whereas the primary trial reported 16 cases.\n\nHowever, this is contradicted by the information provided:\n\n- Primary trial does not report conjunctivitis separately \n- Secondary trial reports 1 case in cohort 2, not 16\n\nTherefore, the numbers presented do not validate or substantiate the comparative relationship asserted between the trials.\n\nThe answer is contradiction, as the statement is refuted by the adverse event data provided."}
{"id": "ec1e269e-470d-43d9-8f23-8a19a5c96fcc", "result": " Contradiction\n\nThe adverse event data from the primary trial shows:\n\nCohort 1:  \n- Anaemia: 7/199 (3.52%)\n- Most common AE was Total: 59/199 (29.65%)\n\nCohort 2:\n- Anaemia: 2/36 (5.56%)   \n- Most common AE was Total: 16/36 (44.44%)\n\nThe statement claims:\n\n- Anaemia was most common in Cohort 1\n- Tachycardia was most common in Cohort 2\n\nHowever, this is contradicted by the numbers provided:\n\n- In Cohort 1, the total AE rate was highest  \n- In Cohort 2, the total AE rate was again the highest reported\n\nNo incidence of \"tachycardia\" is listed for Cohort 2.\n\nTherefore, the adverse event data does not validate or substantiate the specific most common events claimed in the statement. \n\nThe answer is contradiction, as the information presented conflicts with the assertions made."}
{"id": "21611c2a-e6eb-4012-a209-9b6781e1f260", "result": " Entailment\n\nThe primary trial adverse events section states: \n\nAdverse Events 1: \nTotal: 0\n\nThe statement claims:\n\n\"There is no adverse events section in the primary trial\"\n\nThe information provided does not contradict this statement. While an adverse events section title is presented, the actual reported data is:\n\nTotal: 0\n\nThis implies that no adverse events were recorded or reported in the primary trial.\n\nNormatively, if no adverse events occurred, there would be no substantive adverse events data to report. \n\nTherefore, the statement claiming an absence of an adverse events section is precisely validated by the numerical result of \"Total: 0\" provided. \n\nThe answer is entailment, as the primary trial information unambiguously entails and substantiates the assertion made in the statement regarding the absence of an adverse events section.\n\nThe numbers given validate the statement rather than contradicting it in any way."}
{"id": "d1b7105d-0b7d-4b10-92a7-d63243ff0629", "result": "  Entailment\n\nPrimary trial exclusion criteria:\n- Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal)\n\nSecondary trial eligibility criteria: \n- Premenopausal women 55 years of age or younger\n\nThe statement asserts:\n- Patients with low ejection fraction are excluded from primary trial\n- But can be eligible for secondary trial if 55 years or younger\n\nThis is directly validated by comparing the exclusion/eligibility details:\n\n- Primary trial excludes based on low ejection fraction  \n- Secondary trial has no such exclusion, but only criteria is age 55 or younger\n\nNo conflicting information is provided. \n\nThe eligibility/exclusion details unambiguously substantiate what is claimed in the statement regarding the differential treatment of ejection fraction between the two trials.\n\nTherefore, the answer is entailment - the trial information precisely validates the assertion made."}
{"id": "7f3fe97e-68ee-470f-b06e-21cdddb67aa8", "result": " Entailment\n\nPRIMARY TRIAL:\n- Inclusion criteria includes: Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition\n- Specifies stage II-III breast cancer\n\nSECONDARY TRIAL: \n- No inclusion criteria specifies the stage/type of cancer\n- Only requires \"metastatic or advanced solid tumors\" or one of listed cancer types \n\nThe statement claims:\n- Primary trial requires stage 3 breast cancer\n- Secondary trial has no specific cancer stage required\n\nThis is directly validated by comparing the inclusion details:\n\n- Primary trial requires stage II-III breast cancer  \n- Secondary trial does not specify any required cancer stage\n\nNo conflicting information is provided. The eligibility details unambiguously substantiate what is claimed in the statement regarding the cancer stage requirements.\n\nTherefore, the answer is entailment - the trial information precisely validates the assertion made."}
{"id": "ce8464bd-951e-44aa-97d9-10b917b055ce", "result": " Entailment\n\nThe adverse event data reported in the primary trial shows:\n\nCohort 1:\n- Slipped disk: 0/101 (0.00%)\n\nCohort 2:  \n- Slipped disk: 1/98 (1.02%)\n\nThe statement asserts:\n- The percentage of patients with slipped disks was significantly higher in Cohort 2 than Cohort 1\n\nThis is directly validated by the numbers provided:\n\n- Cohort 1 reports 0% patients with slipped disks\n- Cohort 2 reports 1.02% patients with slipped disks \n\nNo other information contradicts what is claimed. \n\nThe adverse event data unambiguously substantiates the comparative relationship between the two cohorts described in the statement regarding slipped disks.\n\nTherefore, the answer is entailment - the primary trial information precisely validates the assertion made in the statement."}
{"id": "0131ebe3-746b-45a5-ba60-fdd326974fec", "result": "  Entailment\n\nPRIMARY TRIAL OUTCOME MEASUREMENT:\n- Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants as defined by RECIST criteria within 6 months.\n\nSECONDARY TRIAL OUTCOME MEASUREMENT: \n- Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the AJCC Staging System. \n\nThe statement asserts:\n- The outcome measurements used are comparable\n\nThe outcome measurements described are directly comparable as they both evaluate:\n\n- Tumor response based on standard criteria (RECIST for primary, AJCC for secondary)\n- Within a similar defined period of treatment/follow up  \n\nNo conflicting details are provided. \n\nThe outcome measurement descriptions unambiguously validate the statement regarding their comparability.\n\nTherefore, the answer is entailment - the trial information precisely substantiates the assertion made in the statement."}
{"id": "b1dd7632-ed92-40a9-9293-bce68619c658", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY criteria specifies:\n\n- Newly diagnosed with stage I-III cancer of the female breast\n\nThe statement claims:\n\n- Patients with stage 4 cancer are excluded \n- Only patients with stage 2 and 3 cancer can be eligible\n\nHowever, this is contradicted by the eligibility criteria - it also allows for stage I cancer patients. \n\nNo where is it stated that only stage 2 and 3 patients are eligible. Stage I patients are also eligible according to the provided information.\n\nThe eligibility details do not validate the restrictions on stage claimed in the statement.\n\nTherefore, the answer is contradiction - the trial information conflicts with the assertions made regarding cancer stages allowed.\n\nThe primary criteria includes stage I patients, not just stage 2 and 3 as stated, so the statement is contradicted."}
{"id": "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION section states:\n\n- Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule\n- Everolimus was administered initially at a dose of 5 mg daily...and then increased to 10 mg PO daily after that.\n\nThe statement asserts:\n\n- Fulvestrant is administered intramuscularly \n- Everolimus is administered orally\n\nThis is directly validated by comparing the intervention details provided:\n\n- Fulvestrant administration route stated as intramuscularly\n- Everolimus administration route implied as oral by mentioning \"PO\" \n\nNo conflicting information is given. \n\nThe intervention description unambiguously substantiates the administration routes claimed in the statement.\n\nTherefore, the answer is entailment - the primary trial information precisely validates the assertions made."}
{"id": "4a15ec5e-4904-4f01-a0a2-c51e83c8c070", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS section reports:\n\n- Outcome Measurement: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients\n- Results for Arm \"Curcumin C3 Complex\" including number of participants and mean score  \n- Results for Arm \"Placebo\" including number of participants and mean score\n\nThe statement asserts: \n\n- The primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort\n\nThis is directly validated by comparing the results reported:\n\n- Results given for both the Curcumin C3 Complex cohort and Placebo cohort \n- Outcome measured is specified as Severity of Dermatitis in Radiation Treatment Site\n\nNo conflicting information provided. The results section unambiguously substantiates reporting the dermatitis severity outcome for both stated cohorts, as claimed in the statement.\n\nTherefore, the answer is entailment - the primary trial results precisely validate the assertions made."}
{"id": "b9e29ea8-6847-40d4-b5c3-81c496101695", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS report:\n\n- Outcome measured is Centrally Assessed Progression Free Survival (PFS) in months \n- For Cohort 1 (Neratinib + Capecitabine), reports Mean PFS as 8.8 months with 95% CI of 7.8 to 9.8 months\n\nThe statement claims:\n\n- All patients in Cohort 1 had a PFS of over 8.8 months \n- Highest PFS was just under 10 months\n\nHowever, this is contradicted by the results reported:\n\n- The mean PFS is provided with a confidence interval, indicating variability in individual patient PFS  \n- It does not report that all patients exceeded the mean of 8.8 months\n\nThe results do not validate that all patients had a PFS over 8.8 months, as stated. \n\nTherefore, the answer is contradiction - the trial information conflicts with the assertions made regarding the PFS values reported.\n\nThe results only report a mean and CI, not individual patient values, so the statement is inaccurate based on the information given."}
{"id": "2a2c16a7-f427-4fdb-8153-94aac304e4b8", "result": " Contradiction\n\nThe PRIMARY TRIAL INTERVENTION provides details for two cohorts:\n\nCohort 1 (HER2+ TC):\n- Cycles 1-3, 4-7, 8-10 have different medications and doses \n- Maximum of 17 cycles with trastuzumab\n\nCohort 2 (HER2+ C):\n- Cycles 1-3, 4-7, 8-10 have different medications and doses\n- No mention of 17 total cycles\n\nThe statement claims:\n- Both cohorts undergo 17 total cycles \n- Receive same medication types and doses throughout all 17 cycles\n\nHowever, this is contradicted by the intervention details:\n\n- Cohorts have different medications/doses in different cycles \n- Only Cohort 1 is stated to receive treatment for maximum 17 cycles\n\nThe information provided does not validate both cohorts receiving identical treatment for 17 total cycles as claimed. \n\nTherefore, the answer is contradiction - the trial details conflict with assertions made in the statement."}
{"id": "618a3ae1-b22c-4c35-86a6-190c1b5b5d21", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria includes:\n\n- Inclusion criteria: Life expectancy 1 year. \n\nThe statement asserts:\n\n- Patients must have a Life expectancy of at least 1 year to enroll in the primary trial.\n\nThis is directly validated by the inclusion criteria listed, which explicitly requires a life expectancy of 1 year.\n\nNo conflicting information is provided. The eligibility details unambiguously substantiate the life expectancy requirement stated in the statement.\n\nTherefore, the answer is entailment - the trial eligibility information precisely validates the assertion made regarding the required life expectancy."}
{"id": "e62f5a3f-0091-4980-9822-db8f4dc2502a", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS section reports:\n\n- Outcome Measurement: Severity of Dermatitis in Radiation Treatment Site \n- Results for Curcumin C3 Complex cohort and Placebo cohort\n\nThe statement asserts:\n\n- Results are reported for both cohorts\n- There is no difference in the results between the two cohorts\n\nHowever, this is contradicted by the actual results reported:\n\n- Curcumin C3 Complex cohort mean is 2.6 \n- Placebo cohort mean is 3.4\n\nThe difference between the reported mean scores indicates there is a difference between the results of the two cohorts.\n\nThe results provided do not validate there being no difference, as explicitly claimed in the statement.\n\nTherefore, the answer is contradiction - the trial results conflict with the assertion that there is no difference between cohort results.  \n\nA difference is clearly shown, so the statement is inaccurate based on the information given."}
{"id": "4a41ac73-538a-43e5-b7ce-8c8e2d56286e", "result": " Entailment\n\nPRIMARY TRIAL ELIGIBILITY:\n- Exclusion criterion: No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago\n\nSECONDARY TRIAL ELIGIBILITY: \n- Exclusion criterion: Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy) \n\nThe statement asserts:\n- Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are receiving adjuvant therapy.\n\nBoth trial eligibility sections validate this statement by explicitly excluding:\n\n- Women with ongoing endocrine therapy (PRIMARY: unless completed 1+ years ago, SECONDARY: prior hormone therapy)\n\nNo conflicting details are provided. The eligibility criteria directly substantiate the assertion made in the statement regarding exclusion of women on endocrine therapy.\n\nTherefore, the answer is entailment - the trials' eligibility information precisely validates the exclusions mentioned in the statement."}
{"id": "75a65913-5655-4377-b441-ecdd4dd75175", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria specifies:\n\n- Newly diagnosed with stage I-III cancer of the female breast\n\nThe statement asserts: \n\n- Patients with stage 4 cancer are excluded from the primary trial\n\nThis is directly validated by the eligibility criteria - it only allows for stage I-III cancer patients. Stage 4 patients are not mentioned as eligible.\n\nNo conflicting information is provided. The eligibility details unambiguously substantiate excluding stage 4 cancer patients, as stated in the statement.\n\nTherefore, the answer is entailment - the trial eligibility information precisely validates the exclusion mentioned in the statement."}
{"id": "1329dec6-fb2c-4219-9db6-3fef9d94b316", "result": "  Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nFor Cohort 1: \n- Left ventricular dysfunction: 2/219 cases\n- Abdominal pain: 1/219 cases\n\nThe statement claims:\n\n- In Cohort 1 there were 10 more cases of Left ventricular dysfunction than Abdominal pain\n\nHowever, this is contradicted by the adverse event details reported:\n\n- Left ventricular dysfunction cases reported as 2 \n- Abdominal pain cases reported as 1\n- The difference between these is 1 case, not 10 cases as stated\n\nThe information provided does not validate there being 10 more cases as asserted. \n\nTherefore, the answer is contradiction - the trial adverse event details conflict with the quantitative claim made in the statement."}
{"id": "29b2fa29-5a76-4877-95bb-1a8de7973d33", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\n- Adverse Events 1 \n- Total adverse events recorded: 6\n\nThe statement asserts:\n\n- Only 6/67 patients in cohort 1 suffered adverse events\n\nThis is directly validated by the adverse events details provided:\n\n- Total adverse events listed is 6\n- The denominator given for percentage calculations is 67 patients \n\nNo conflicting information is presented. The adverse event reporting unambiguously substantiates that 6 out of 67 patients experienced adverse events, as stated.\n\nTherefore, the answer is entailment - the trial adverse event information precisely validates the assertion made regarding the number of patients affected."}
{"id": "7edba90d-076d-4f55-b9d6-a1765ceb48bd", "result": "  Contradiction  \n\nPRIMARY TRIAL INTERVENTION:\n- Provides details of intraductal administration \n\nSECONDARY TRIAL INTERVENTION:  \n- INTERVENTION 1: Cetuximab is given IV over 60-120 minutes\n\nThe statement claims:\n\n- Primary and secondary trial participants do not receive any medication by IV\n\nHowever, this is contradicted by the secondary trial intervention which specifies cetuximab is administered intravenously.\n\nNo details are provided about the primary trial route of administration. But the secondary trial details directly conflict with the claim that no IV medication is given.\n\nTherefore, the answer is contradiction - the secondary trial intervention information conflicts with the assertion that no IV medication is received.\n\nThe intervention section unambiguously shows IV administration occurring, contradicting the statement."}
{"id": "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS report:\n\n- Outcome Measurement: Number of Participants With Disease Progression (PD) or Death\n- Results 1 reports Arm \"Fulvestrant and Dasatinib\" had 35/50 participants with PD or death\n- Results 2 reports Arm \"Fulvestrant\" had 40/49 participants with PD or death \n\nThe statement claims:\n\n- Patients receiving Fulvestrant were much more likely to suffer PD or death than patients receiving Herceptin\n\nHowever, this is a contradiction, as:\n\n- No results are reported for an arm receiving Herceptin\n- Only results for Fulvestrant +/- Dasatinib arms are provided \n\nThe trial results do not include any data to validate comparing rates of PD/death for Fulvestrant vs. Herceptin, as no Herceptin arm is mentioned. \n\nTherefore, the statement cannot be validated based on the information given and contradicts what is reported.\n\nThe answer is contradiction, as the claim involves an unsupported comparison."}
{"id": "1314146f-2869-4525-8034-7f732d238385", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports adverse event rates for:\n\n- Cohort 1 with N=1612 patients \n- Cohort 2 with N=1623 patients\n\nThe statement asserts:\n\n- None of the individual adverse events affect more than 100 patients\n\nThis is validated based on the adverse event details reported:\n\n- The highest individual adverse event rate reported is 21.09% (340/1612 patients) for Total adverse events in Cohort 1\n- No other individual adverse event rate exceeds 100 patients \n\nThere is no conflicting information provided. The adverse event reporting substantiates that no single adverse event impacted more than 100 patients, as stated.\n\nTherefore, the answer is entailment - the trial adverse event information precisely validates the assertion made in the statement."}
{"id": "7c7418d2-32d7-4517-874b-eb3db24ea16a", "result": "  Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria includes:\n\n- Inclusion Criteria: \n- Age between 18 years and 70 years.\n- Karnofsky performance status index > 80 %. \n- Adequate hepatic, renal and heart functions.\n- Adequate hematology levels.\n\nThe statement asserts:\n\n- To be eligible candidates must be over 18, have a Karnofsky score over 80 and adequate hepatic, renal, heart functions and hematology levels.\n\nThis is directly validated by the inclusion criteria listed, which explicitly requires these eligibility parameters. \n\nNo conflicting information is provided. The eligibility details unambiguously substantiate the criteria mentioned in the statement.\n\nTherefore, the answer is entailment - the trial eligibility information precisely validates the assertion made regarding eligibility requirements."}
{"id": "1f6a14ae-e22b-4b40-b389-217570dbf38e", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS report:\n\n- Outcome Measurement: Number of Dose Limiting Toxicities \n- Results 1 for Cohort 1 with N=6 patients had 2 DLTs\n- Results 2 for Cohort 2 with N=2 patients had 1 DLT\n\nThe statement asserts: \n\n- 50% of Cohort 2 patients suffered DLTs\n\nHowever, this contradicts the reported results:\n\n- Cohort 2 had a total of 2 patients \n- 1 patient suffered a DLT\n- 1/2 is not equal to 50%\n\nThe trial results do not validate that 50% of Cohort 2 suffered DLTs, as reported DLT rate is 1/2 or 50%.\n\nTherefore, the statement cannot be validated and contradicts the information given in the trial results. \n\nThe answer is contradiction."}
{"id": "5c1e360c-fd93-4dd4-b855-71ba416d34cb", "result": "   Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY information includes:\n\n- Inclusion criteria: Able to swallow an oral medication\n\nThe statement asserts: \n\n- Patients must be able to receive medication orally to participate\n\nThis criteria is directly validated by the inclusion criteria requiring the ability to swallow an oral medication.\n\nNo conflicting details are provided. The eligibility criteria unambiguously substantiate the oral administration requirement mentioned in the statement.\n\nTherefore, the answer is entailment - the trial eligibility information precisely validates the assertion made regarding an oral medication capability."}
{"id": "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d", "result": " Entailment\n\nPRIMARY TRIAL ADVERSE EVENTS reports:\n- Adverse Events 1 \n- Total adverse events: 0/23 (0.00%)\n\nSECONDARY TRIAL ADVERSE EVENTS reports:\n- Adverse Events 1  \n- Total adverse events: 0/655 (0.00%)\n- Adverse Events 2\n- Total adverse events: 0/580 (0.00%)\n\nThe statement asserts:\n- The primary and secondary trials report the same types of adverse events\n\nThis is directly validated as both trial sections only report \"Total\" adverse events with a rate of 0.00%. \n\nNo other or differing adverse event types are listed between the two trials.\n\nThe adverse event information provided unambiguously substantiates that the same single type of adverse event (\"Total\") is reported for both trials, as stated.\n\nTherefore, the answer is entailment - the trials' adverse event details precisely validate the assertion made regarding reporting the same event types."}
{"id": "48f516ff-abb4-4312-9b00-02f53fb16218", "result": "  Contradiction \n\nThe PRIMARY TRIAL RESULTS report:\n\n- Outcome Measurement: Pathologic Complete Response\n- Results 1 for Intervention Arm with N=32 patients reports 26 participants experienced PCR\n\nThe statement asserts:\n\n- Under a quarter of patients in the intervention arm experienced PCR\n\nHowever, this contradicts the reported results:\n\n- The intervention arm had 32 total patients\n- 26 patients experienced PCR \n- 26/32 is more than a quarter (25%) of the total patients\n\nThe trial results do not validate less than 25% achieving PCR as reported rate is 26/32 or 81.25%.\n\nTherefore, the statement cannot be validated and contradicts the information given in the trial results.\n\nThe answer is contradiction."}
{"id": "978d19fc-e7f6-485e-b8bd-cfcde06441ab", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- DISEASE CHARACTERISTICS: \n- Histologically confirmed stage I, II, or III breast cancer\n- T1-3, N0-2, M0\n\nThe statement asserts: \n\n- T1 N0 M0 patients are eligible\n\nT1 N0 M0 falls within the reported disease characteristics of stage I-III and T1-3, N0-2, M0.\n\nNo conflicting information is provided. The eligibility details unambiguously include T1 N0 M0 patients as stated.\n\nTherefore, the answer is entailment - the trial eligibility information precisely validates the assertion made regarding T1 N0 M0 eligibility."}
{"id": "0a6d1b4c-244e-44e2-a229-62e4cbdfa979", "result": "  Entailment\n\nThe PRIMARY TRIAL RESULTS report outcomes related to toxicities.\n\nThe SECONDARY TRIAL RESULTS report outcomes related to tumor response. \n\nThe statement asserts:\n\n- The results of the secondary and primary trials are non-comparable.\n\nThis is directly validated, as the primary trial measures safety outcomes while the secondary trial measures efficacy outcomes. \n\nThe different outcome measurements reported unambiguously substantiate that a direct comparison of results is not valid, as asserted.\n\nTherefore, the answer is entailment - the differing outcome types reported precisely validate the statement that the results are non-comparable.\n\nNo conflicting information is presented - the outcome measurements substantiate non-comparability as claimed."}
{"id": "9bcc31df-c1f6-4785-9235-f673213acf3a", "result": "  Entailment\n\nThe PRIMARY TRIAL INTERVENTION details:\n\n- Intervention 1: Docetaxel 100 mg/m^2 \n- Intervention 2: Docetaxel 100 mg/m^2\n\nThe statement asserts:\n\n- Both cohorts receive identical doses of Docetaxel\n\nThis is directly validated by the intervention information reporting both arms receive docetaxel at a dose of 100 mg/m^2.\n\nNo conflicting information is provided. The intervention descriptons unambiguously substantiate the claim of identical docetaxel dosing between cohorts.\n\nTherefore, the answer is entailment - the trial intervention description precisely validates the assertion made regarding identical docetaxel doses."}
{"id": "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9", "result": "  Contradiction\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\n- Intervention 1: No Exercise + Calcitriol pill taken once per week  \n- Intervention 2: Exercise + Calcitriol pill taken once per week\n\nThe statement asserts:\n\n- Neither cohort undergoes surgery or receives oral medication \n\nHowever, this contradicts the intervention details provided:\n\n- Intervention 1 involves taking an oral calcitriol pill\n- Intervention 2 also involves taking an oral calcitriol pill\n\nThe trial intervention does not support the claim that no oral medication is received, as calcitriol pills are specified.\n\nTherefore, the statement is contradicted by the information given and cannot be validated. \n\nThe answer is contradiction, as the intervention description does not substantiate the assertion that no oral medication is received."}
{"id": "75cf4ec2-9f2b-4d5b-8772-af247eaca07b", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- DISEASE CHARACTERISTICS:\n  - Histologically confirmed breast cancer\n  - Metastatic (stage IV) disease\n\nThe statement asserts:\n\n- Patients with stage I-III breast cancer are not eligible\n\nThis is directly validated by the inclusion of only stage IV disease in the eligibility criteria. Stage I-III disease is explicitly excluded.\n\nNo conflicting information is provided. The eligibility details unambiguously substantiate that non-metastatic/stage I-III patients are not eligible, as stated.\n\nTherefore, the answer is entailment - the trial eligibility information precisely validates the assertion made regarding ineligibility of stage I-III patients."}
{"id": "553f00ea-5197-4233-b1e0-e5727856b599", "result": " Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS reports:\n\n- Adverse Events 1\n- Total adverse events: 2/30 (6.67%) \n- Dry Eyes: 1/30 (3.33%)\n- Diarrhea: 1/30 (3.33%)\n\nThe statement asserts:\n\n- No cardiac or bowel-related adverse events were recorded\n\nHowever, this is contradicted by the reported adverse events, which includes:\n\n- Diarrhea, a bowel-related adverse event\n\nThe trial adverse event section does not support the claim that no bowel adverse events occurred, as diarrhea is explicitly listed. \n\nTherefore, the statement is contradicted by the information provided and cannot be validated.\n\nThe answer is contradiction, as the adverse event description conflicts with the assertion that no bowel events were recorded."}
{"id": "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32", "result": " Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS reports:\n- Adverse Events 1 \n- Total adverse events: 0/150 (0.00%) \n\n- Adverse Events 2 does not report any events\n\nThe SECONDARY TRIAL ADVERSE EVENTS reports:\n- Anemia 1/41 (2.44%)\n- No mention of mental health disorders, PLEUROPERICARDITIS or ATRIAL THROMBOSIS\n\nThe statement asserts:\n- There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS and Anemia in the secondary trial.\n\nHowever, this contradicts the reported information:\n\n- No cases of the specified adverse events are reported in either trial \n- Only Anemia is reported, and at a lower rate in the secondary trial\n\nTherefore, the statement cannot be validated and is contradicted by the adverse event sections reported. \n\nThe answer is contradiction, as the event rates do not match what is claimed in the statement."}
{"id": "215a5c4a-d90c-4500-8284-0679ce311734", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY includes the following inclusion criterion:\n\n- ErbB2(HER2)overexpressing breast cancer. \n\nThe statement asserts:\n\n- Patients must have HER2- breast cancer to participate.\n\nHowever, this contradicts the inclusion criteria provided, which explicitly requires HER2 overexpression (positive), not HER2 negative status as stated.\n\nNo other information is given that would validate HER2 negative eligibility. The eligibility details unambiguously contradict the assertion made in the statement.\n\nTherefore, the answer is contradiction - the trial eligibility criteria conflict with the statement regarding participation of HER2- breast cancer patients. The criteria only allow HER2 positive disease."}
{"id": "e9a4bd91-f58b-4234-9037-75e0699d1bbd", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION reports:\n\n- INTERVENTION 1: Pralatrexate, 190 mg/m^2 for 2 to 4 weeks\n\nThe statement asserts: \n\n- The primary trial participants receive less than 300mg/m^2 doses of Pralatrexate\n\nThis is directly validated by the intervention specifying a dose of 190 mg/m^2, which is unambiguously less than 300 mg/m^2 as stated.\n\nNo conflicting information is provided. The intervention description precisely matches the dose range claimed in the statement.\n\nTherefore, the answer is entailment - the trial intervention substantiates the assertion regarding doses being less than 300mg/m^2 by reporting a maximum dose of 190 mg/m^2."}
{"id": "7d52734c-0801-413d-9ae2-d190b972cde5", "result": " Contradiction \n\nThe PRIMARY TRIAL RESULTS report outcomes in terms of:\n- Number of Participants With Complete Pathologic Response\n- Assessed at 8 weeks\n\nThe SECONDARY TRIAL RESULTS report outcomes in terms of:  \n- Change in Masood Score\n- Mean and standard deviation reported\n- No time unit reported \n\nThe statement asserts:\n- The results can be compared by changing the units from days to months\n\nHowever, this is contradictory as the primary trial reports a count variable assessed at a specific time point, while the secondary reports a continuous variable with no time unit. \n\nMerely changing the time units would not render the outcomes comparable, as they are fundamentally different parameter types.\n\nTherefore, the information given does not validate that the results can be directly compared by the proposed unit conversion. \n\nThe answer is contradiction, as the reported outcomes are shown to be non-comparable."}
{"id": "5de9caeb-9dd5-4535-8fe3-289450d9c626", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS report:\n\n- Lapatinib Plus Capecitabine arm: 8/251 participants with CNS metastases \n- Trastuzumab Plus Capecitabine arm: 12/250 participants with CNS metastases\n\nThe statement asserts:\n\n- The Trastuzumab Plus Capecitabine group had a higher percentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.\n\nThis is directly validated by the results presented - the Trastuzumab arm had 12/250 events compared to 8/251 in the Lapatinib arm, substantiating the higher percentage as stated. \n\nNo conflicting information is provided. The trial results unambiguously support the claim made in the statement.\n\nTherefore, the answer is entailment - the primary trial results precisely validate the assertion regarding the comparative CNS metastases percentages between groups."}
{"id": "bebfc78e-b35f-4677-8342-9567a7e795a1", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS do not report any cases of diarrhea.\n\nThe SECONDARY TRIAL ADVERSE EVENTS report:\n\n- Adverse Events 1: Total 0/92 (0.00%), Diarrhea 0/92 (0.00%)  \n- Adverse Events 2: Total 1/93 (1.08%), Diarrhea 1/93 (1.08%)\n\nThe statement asserts: \n\n- There is one case of diarrhea in the secondary trial and none in the primary trial\n\nThis is directly validated by the adverse event sections reported - the primary trial reports no diarrhea, while the secondary reports 1 case.\n\nNo conflicting information is provided. The adverse event descriptions precisely match what is claimed in the statement.\n\nTherefore, the answer is entailment - the trial adverse event information unambiguously substantiates the statement regarding diarrhea case numbers between trials."}
{"id": "faa65e54-aa04-4595-8dae-05cf00b4c887", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\n- INTERVENTION 1: Ipatasertib + Paclitaxel\n- INTERVENTION 2: Placebo + Paclitaxel\n\nThe statement asserts:\n\n- Only cohort 1 patients are administered Ipatasertib\n\nThis is directly validated by the intervention details provided. INTERVENTION 1 explicitly involves administration of Ipatasertib, while INTERVENTION 2 uses placebo. \n\nNo conflicting information is presented. The intervention unambiguously matches the claim in the statement that only cohort 1 receives Ipatasertib.\n\nTherefore, the statement is entailed by the trial intervention information reported. The administration of Ipatasertib is precisely limited to cohort 1 as stated.\n\nThe answer is entailment, as the primary trial intervention substantiates the assertion regarding Ipatasertib administration."}
{"id": "751fd763-89fa-4d52-8bda-f09b490a5e78", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS report the outcome measurement as:\n\n- Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)\n\nThe statement asserts: \n\n- There were no recorded deaths in the primary trial cohorts\n\nHowever, this contradicts the definition of \"Event\" provided in the results, which explicitly includes \"Death (From Any Cause)\" as one of the events being measured.\n\nWhile the exact numbers of deaths are not reported, the inclusion of death as an event means deaths must have been recorded, contradicting the statement.\n\nNo information is given that would validate the claim that no deaths were recorded. Therefore, the primary trial results contradict the statement.\n\nThe answer is contradiction, as the reported outcome definition conflicts with the assertion of no recorded deaths."}
{"id": "c40fdf91-9f81-454a-bba9-ec5c950cef6e", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\n- INTERVENTION 1: Lapatinib 1500 mg\n- INTERVENTION 2: Placebo\n\nThe statement asserts:\n\n- One patient cohort in the primary trial received a placebo intervention\n\nThis is directly validated by INTERVENTION 2, which explicitly states one cohort received placebo.\n\nNo conflicting information is presented. The intervention section precisely matches the claim in the statement regarding one cohort receiving placebo.\n\nTherefore, the statement is entailed by the primary trial intervention details reported. The inclusion of a placebo cohort as described unambiguously substantiates the assertion.\n\nThe answer is entailment, as the trial intervention information unambiguously validates the statement about a placebo cohort."}
{"id": "31105b43-832b-48bc-a78d-ee90c155ca44", "result": "  Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- Presence of hot flashes for 30 days prior to study registration\n\nThe SECONDARY TRIAL ELIGIBILITY does not mention any criteria related to hot flashes.\n\nThe statement asserts: \n\n- Presence of hot flashes for 30 days prior to study registration is required for the primary trial, but not for the secondary trial.\n\nThis is directly validated by the eligibility criteria reported - the primary trial explicitly requires hot flashes, while the secondary does not mention this criterion.\n\nNo conflicting information is provided. The eligibility sections precisely match what is claimed in the statement.\n\nTherefore, the statement is entailed by the trial eligibility details. The difference in hot flash requirements between trials as stated is unambiguously supported.\n\nThe answer is entailment, as the eligibility criteria substantiate the assertion regarding hot flash criteria."}
{"id": "49ba06b2-576d-4db2-80b6-51673416f2ba", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS report the outcome measurement as:\n\n- Percent Change in Net Influx Constant (Ki) by FLT PET \n\nThe SECONDARY TRIAL RESULTS report the outcome measurement as:\n\n- Progression-Free Survival (PFS) as Assessed by Investigator Using RECIST\n\nThe statement asserts:\n\n- Both trials measure Percent Change in Net Influx Constant (Ki) by FLT PET\n\nHowever, this is contradictory. While the primary trial measures percent change in Ki by FLT PET, the secondary trial measures PFS by RECIST - not the FLT PET outcome.\n\nNo information is provided that would validate the secondary trial also measuring change in Ki by FLT PET. \n\nTherefore, the reported results contradict the statement, as the outcomes measured are shown to be different between the two trials.\n\nThe answer is contradiction, as the outcome measurements described do not match what is claimed."}
{"id": "3cb71095-8e01-40dc-bbf5-eeffed55f354", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- Histologically confirmed breast cancer  \n- Metastatic (stage IV) disease\n\nThe statement asserts:\n\n- Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial\n\nHowever, this contradicts the eligibility criteria explicitly reported - histologically confirmed breast cancer is listed under disease characteristics and stage IV disease is specified. \n\nNo information provided validates excluding stages I-III. The eligibility details unambiguously allow stage IV disease, contradicting the statement.\n\nTherefore, the primary trial eligibility information conflicts with the assertion that patients with stage I-IV disease are ineligible. \n\nThe answer is contradiction, as the trial criteria described do not match the restrictions claimed in the statement."}
{"id": "09fc4356-6154-427e-b710-ed5df6470aff", "result": "  Contradiction\n\nThe PRIMARY TRIAL RESULTS report:\n\nResults 1: \n- AZD8931 160 mg bd cohort:\nEye disorders: Keratitis: 1\n\nResults 2:\n- AZD8931 120 mg bd cohort:  \nEye disorders: Keratitis: 0\n\nThe statement asserts:\n\n- 50% of cohort 2 patients suffered Keratitis\n\nHowever, this contradicts the results reported - cohort 2 had 0 cases of keratitis, not 50% as claimed. \n\nNo information provided validates the 50% figure. The results explicitly show 0 keratitis cases in cohort 2.\n\nTherefore, the statement is contradicted by the numbers given in the primary trial results.\n\nThe answer is contradiction, as the actual results reported do not match what is asserted."}
{"id": "446f3c69-0de5-475c-a8e2-ff40ece90672", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include the following inclusion criterion:\n\n- HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies\n\nThe statement asserts:\n\n- Only patients with HER2+ve breast cancer are eligible for the primary trial\n\nThis is directly validated by the inclusion criteria reported, which explicitly specifies HER-2 positivity as a requirement. \n\nNo conflicting information is presented. The eligibility criteria precisely match the claim in the statement regarding patient HER2 status eligibility.\n\nTherefore, the statement is entailed by the primary trial eligibility details provided. The HER2 inclusion criterion unambiguously substantiates the assertion.\n\nThe answer is entailment, as the trial eligibility information directly validates the statement about HER2 eligibility."}
{"id": "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS report:\n\nResults 1: \n- Neratinib 160 mg + Paclitaxel arm: Participants 0, 0.0%  \n\nResults 2:\n- Neratinib 240 mg + Paclitaxel arm: Participants 0, 0.0%\n\nThe statement asserts:\n\n- The primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects\n\nThis is directly validated by the results reported - both arms explicitly report 0 participants, which is 0.0% of patients, suffering dose limiting toxicities.\n\nNo conflicting information is provided. The actual results precisely match what is claimed in the statement.\n\nTherefore, the statement is entailed by the primary trial results. The percentage of patients reporting 0 side effects as stated is unambiguously substantiated.  \n\nThe answer is entailment, as the trial results directly validate the assertion made."}
{"id": "f0e845f9-8991-45b5-a520-51e934756f7a", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\n- INTERVENTION 1: Letrozole orally once daily\n\nThe SECONDARY TRIAL INTERVENTION describes: \n\n- INTERVENTION 1: Sentinel Lymph Node Biopsy\n\nThe statement asserts:\n\n- The primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.\n\nThis is directly validated by the intervention descriptions provided. The primary trial clearly involves an oral drug, while the secondary trial intervention involves a medical biopsy procedure.\n\nNo conflicting information is presented. The interventions precisely match what is claimed in the statement regarding their nature.\n\nTherefore, the statement is entailed by the trial intervention details reported. The difference between an oral drug versus a medical procedure, as stated, is unambiguously supported.\n\nThe answer is entailment, as the intervention sections directly validate the characteristics of the interventions asserted in the statement."}
{"id": "a0065d58-e03b-4dd0-9c81-cbbf651a6d45", "result": "  Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+ or FISH/CISH negative) status. \n\nThe SECONDARY TRIAL ELIGIBILITY criteria include:\n\n- ErbB2(HER2)overexpressing breast cancer.\n\nThe statement asserts:\n\n- Any patient eligible for the secondary trial will also be eligible for the primary trial\n\nHowever, this is contradicted by the eligibility criteria reported. The primary trial explicitly requires HER2-negative status, while the secondary trial requires HER2-overexpressing status. \n\nNo information provided would validate a patient being eligible for both based on contradictory HER2 criteria. \n\nTherefore, the eligibility details conflict with the assertion that any secondary trial eligible patient would also meet primary trial criteria.\n\nThe answer is contradiction, as the HER2 eligibility mismatch described does not support the statement."}
{"id": "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n\nThe statement asserts: \n\n- ECOG score > 2 is necessary to be eligible for the primary trial\n\nHowever, this is contradicted by the eligibility criteria reported. The criteria specify an ECOG score of 0 or 1, not >2 as stated.\n\nNo information provided would validate an ECOG score >2 being required. \n\nTherefore, the stated ECOG score eligibility does not match what is explicitly described in the reported criteria.\n\nThe answer is contradiction, as the eligibility details conflict with the assertion in the statement regarding the necessary ECOG score.\n\nThe criteria unambiguously indicate only scores of 0 or 1 are permitted, directly contradicting the claim of >2 being required."}
{"id": "973f090a-8967-4d75-bb8e-6166c868337c", "result": " Contradiction\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\nINTERVENTION 1: Ipatasertib + Paclitaxel\nINTERVENTION 2: Placebo + Paclitaxel \n\nIt does not specify any dose amounts or cohorts.\n\nThe statement asserts:\n\n- Cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and Placebo than cohort 2 patients\n\nHowever, this contradicts the intervention details provided, as no cohorts or dose amounts are mentioned. \n\nNo information given validates comparing doses between cohorts, as cohorts and doses are not described at all.\n\nTherefore, the intervention section does not entail or support the dosage comparison between cohorts as stated. This dosage differentiation is not represented in the reported intervention descriptions.\n\nThe answer is contradiction, as the actual intervention details do not match what is claimed regarding cohorts and relative dosing in the statement.\n\nThe intervention information alone does not substantiate the assertion made about cohort doses."}
{"id": "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include: \n\n- Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ\n- The tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter. \n\nThe statement asserts:\n\n- Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial\n\nHowever, this contradicts the eligibility criteria reported. The criteria specify breast cancer lesions only, not carcinomas in the stomach or neck.\n\nNo information provided would validate eligibility requiring lesions in other locations.\n\nTherefore, the stated lesion locations do not match what is explicitly described in the reported eligibility criteria regarding breast cancer involvement only. \n\nThe answer is contradiction, as the eligibility details directly conflict with the assertion made about required lesion sites in the statement.\n\nThe criteria unambiguously involve breast cancer, contradicting the claim of stomach and neck carcinomas being necessary."}
{"id": "1d1f57f8-85f7-448c-a4bb-15957da568fd", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\nINTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression\n\nThe statement asserts: \n\n- The primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression\n\nThis is directly validated by the intervention details reported. The protocol explicitly specifies administration of pemetrexed every 14 days until complete response or disease progression occurs.\n\nNo conflicting information is presented. The continuation criteria precisely matches what is claimed in the statement.\n\nTherefore, the statement is entailed by the primary trial intervention description. The continuation endpoints stated are unambiguously supported.\n\nThe answer is entailment, as the intervention section directly validates the intervention protocol timeline asserted in the statement.\n\nThe continuation details precisely correspond to the claim regarding continuing treatment until specified response or progression endpoints."}
{"id": "9f7d476e-9db3-4c00-abe6-4c2f0160470a", "result": "  Contradiction \n\nThe PRIMARY TRIAL RESULTS report:\n\nResults 1:\nArm/Group Title: Intervention Arm  \nUnit of Measure: percentage of participants 26\n\nThe statement asserts:\n\n- Under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response\n\nHowever, this contradicts the results reported. The intervention arm results explicitly state the percentage achieving pathologic complete response was 26 participants out of the 32 analyzed, which is 26/32 = 81.25%\n\nNo information provided validates the under 30% figure. The actual percentage given in the results is over 30%.\n\nTherefore, the percentage of patients reported to experience the outcome does not match what is claimed in the statement. \n\nThe answer is contradiction, as the stated percentage is refuted by the number presented in the primary trial results."}
{"id": "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d", "result": "   Contradiction\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\nINTERVENTION 1: Docetaxel 100 mg/m^2 Plus Placebo  \nINTERVENTION 2: Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg\n\nThe statement asserts: \n\n- Both cohorts receive identical Docetaxel doses, with cohort 1 also receiving 100 mg/m^2 of Placebo\n\nHowever, this contradicts the intervention details provided. Cohort 1 receives placebo, not 100 mg/m^2 of placebo as stated. \n\nNo information validates the dosage of placebo mentioned in the statement. \n\nTherefore, the dosage of placebo described does not match what is actually specified in the reported intervention - placebo without an amount.\n\nThe answer is contradiction, as the stated placebo dosage is not represented in the intervention descriptions. The details conflict with the assertion made.\n\nThe intervention information alone does not substantiate the claim about cohort placebo dosing."}
{"id": "3adcc8fc-b76b-407a-a006-729a13f571fb", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION describes:\n\nINTERVENTION 1: Nivolumab + Daratumumab (TNBC) \nINTERVENTION 2: Nivolumab + Daratumumab (NSCLC)\n\nThe statement asserts:\n\n- Both cohorts receive identical interventions, the difference is cancer type, with cohort 1 having HER2+ cancer and cohort 2 being PR- \n\nThis is directly validated by the intervention details reported. Both cohorts receive the same drugs at the same doses and schedules. The only difference specified is the type of cancer, with cohort 1 noted as TNBC and cohort 2 as NSCLC.\n\nNo conflicting information is presented. The interventions and distinction between cohorts precisely matches what is claimed in the statement.\n\nTherefore, the statement is entailed by the primary trial intervention description. The assertion regarding identical interventions and sole distinction of cancer type is unambiguously supported.\n\nThe answer is entailment, as the intervention section directly validates the characteristics of the cohorts and interventions as stated."}
{"id": "68379456-775b-463b-bfdb-d8aa42c9124b", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY criteria include:\n\n- Females with histologic or cytologic diagnosis of advanced breast cancer.\n\nThe SECONDARY TRIAL ELIGIBILITY criteria include: \n\n- Confirmed hormone receptor positive advanced breast cancer, postmenopausal women\n\nThe statement asserts:\n\n- Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial\n\nBoth trial eligibility sections validate this statement:\n\n- The primary trial requires female patients with advanced breast cancer \n- The secondary trial also requires confirmed advanced breast cancer\n\nNo conflicting information is presented. The eligibility criteria precisely match what is claimed in the statement regarding requirements to be female and have advanced breast cancer.\n\nTherefore, the statement is entailed by the eligibility criteria reported for both trials. \n\nThe answer is entailment, as the trial details directly support the eligibility characteristics stated in the assertion."}
{"id": "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY criteria do not mention endocrine therapy as an exclusion criteria.\n\nThe SECONDARY TRIAL ELIGIBILITY criteria also do not mention endocrine therapy as an exclusion criteria. \n\nThe statement asserts:\n\n- Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial\n\nHowever, this is contradictory to both trial eligibility sections provided, as neither one lists current endocrine therapy as an exclusion criteria.\n\nTherefore, the exclusion details do not match what is claimed in the statement regarding endocrine therapy.\n\nThe answer is contradiction, as the statement presents an exclusion criteria that is not represented or supported in the actual eligibility information reported for the two trials. The criteria presented conflict with the assertion.\n\nWhile hormone receptor status may affect eligibility, current endocrine therapy itself is not specified as an exclusion based on the data given."}
{"id": "f04d9695-81b8-4d70-877b-59caddf901bd", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports 0 adverse events.\n\nThe SECONDARY TRIAL ADVERSE EVENTS sections report:\n\nAdverse Events 1: Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)\n\nAdverse Events 2 does not report any Dyspnea events.\n\nThe statement asserts: \n\n- Between the two trials, all recorded cases of Dyspnea occurred in cohort 1 of the secondary trial\n\nThis is directly supported by the adverse event sections. Dyspnea is only reported in Adverse Events 1 of the secondary trial. \n\nNo conflicting information is presented. The occurrence of Dyspnea precisely matches what is claimed in the statement.\n\nTherefore, the statement is entailed by the adverse event descriptions provided for the two trials.\n\nThe answer is entailment, as the adverse event details unambiguously validate the assertion regarding Dyspnea events."}
{"id": "f42e1874-343a-43ed-bb0c-884509c4793c", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS report measuring:\n\n- Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) \n\nThe SECONDARY TRIAL RESULTS report measuring:\n\n- Progression Free Survival (PFS) is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause.\n\nThe statement asserts:\n\n- The primary trial measures percentage of participants with objective response whereas the secondary trial measures number of participants with disease progression (PD) or death\n\nHowever, this contradicts the actual results reported. The secondary trial measures PFS, not number of participants with PD or death specifically. \n\nTherefore, the outcome measures described do not match what is claimed in the statement.\n\nThe answer is contradiction, as the statement is refuted by the results details provided for the two trials. The measures presented conflict with the assertion."}
{"id": "30483d7e-7703-459c-bd10-e2bd259c2a4f", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1:\nTotal: 4/65 (6.15%)  \nAnaemia * 0/65 (0.00%)\nFebrile neutropenia * 0/65 (0.00%)\nLeukopenia * 0/65 (0.00%)\nNeutropenia * 0/65 (0.00%)\n\nThe statement asserts:\n\n- There were two types of adverse events which did not affect any patients in cohort 1 \n\nThis is directly supported by the adverse event data reported. Anaemia and Febrile neutropenia are the two adverse events listed that did not affect any patients (reported as 0/65 patients) in Adverse Events 1.\n\nNo conflicting information is presented. The adverse events specified precisely match those claimed to have not affected any cohort 1 patients.\n\nTherefore, the statement is entailed by the primary trial adverse event reporting. \n\nThe answer is entailment, as the adverse event details unambiguously validate the assertion made."}
{"id": "7cde9a22-a91f-4feb-892d-7cbd35f96a27", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS section reports:\n\nOutcome Measurement: Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 \n\nIt then provides the results for two cohorts:\n\nResults 1: Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim\nResults 2: Arm/Group Title: Ixabepilone\n\nListing the mean change in tumor size for each cohort.\n\nThe statement asserts:\n\n- The primary trial reports the changes in tumor size for patients in its cohorts.\n\nThis is directly supported by the results reported. The outcome measurement and results presented unambiguously reflect changes in tumor size for the two cohorts.\n\nNo conflicting information is presented. The results precisely validate what is claimed in the statement regarding reporting of tumor size changes.\n\nTherefore, the statement is entailed by the primary trial results provided. \n\nThe answer is entailment, as the results section unambiguously supports the assertion made."}
{"id": "16c29502-4683-4087-9410-ff1b786556f5", "result": " Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports: \n\nAdverse Events 1:\nTotal: 14/41 (34.15%)\nConstipation 1/41 (2.44%)\n\nThe statement asserts:\n\n- The least common adverse event in the primary trial was Constipation\n\nHowever, this is contradictory to the adverse event data reported. While Constipation affected 1/41 patients, the same rate is reported for several other adverse events including:\n\nAnemia \nFebrile neutropenia\nEye disorders - Other, Visual disturbance \nAbdominal pain\nNausea\nFever\nPain\n\nTherefore, Constipation was not the least common adverse event, as per the numbers reported it was equally as common as some other events. \n\nThe answer is contradiction, as the assertion that Constipation was the least common is refuted by the adverse event frequencies listed."}
{"id": "5c975af8-6b7f-4a5d-b4a6-257c76763ce9", "result": " Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS sections are blank, reporting no data. \n\nThe SECONDARY TRIAL ADVERSE EVENTS sections report:\n\nAdverse Events 1: \nAcute myocardial infarction 0/199 (0.00%)\nCardiopulmonary failure 1/199 (0.50%) \nSupraventricular tachycardia 0/199 (0.00%)\n\nAdverse Events 2:\nAcute myocardial infarction 1/36 (2.78%)\nCardiopulmonary failure 0/36 (0.00%)\nSupraventricular tachycardia 1/36 (2.78%)\n\nThe statement asserts there were more cases of these 3 adverse events in the secondary trial cohort 1 than the entire primary trial cohort.\n\nHowever, this contradicts the data provided, as the primary trial reports no adverse event data to compare to.\n\nTherefore, the adverse event occurrence comparison described does not align with the information given. \n\nThe answer is contradiction, as the statement cannot be validated or refuted based on the trial details. The assertion is not supported."}
{"id": "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS sections report:\n\nAdverse Events 1: \nTotal: 13/61 (21.31%)\n\nAdverse Events 2:\nTotal: 12/60 (20.00%)\n\nThe statement asserts:\n\n- There were more total AEs in cohort 1 of the primary trial than cohort 2\n\nThis is directly supported by the reported data. Adverse Events 1 reports a total of 13/61 AEs, while Adverse Events 2 reports a total of 12/60 AEs.\n\nNo conflicting information is presented. The relative total AEs between the two cohorts precisely matches what is claimed in the statement. \n\nTherefore, the statement is entailed by the adverse event details provided.\n\nThe answer is entailment, as the adverse event statistics unambiguously validate the assertion regarding more total AEs in cohort 1."}
{"id": "8e91e404-086e-4063-8d54-83d1b8ebd969", "result": " Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1: \nTotal: 6\nReports individual AEs affecting 1/67 patients each.\n\nThe statement asserts:\n\n- Over 1/6 patients in cohort 1 suffered adverse events\n\nHowever, this statement contradicts the data reported. \n\nAdverse Events 1 lists individual AEs affecting 1/67 patients each, for a total of 6 AEs. \n\n1/6 of 67 patients would be over 11 patients. But the data only reports 6 total AEs, not over 11 patients experiencing AEs.\n\nTherefore, the reported frequency of patients experiencing AEs does not match the assertion made in the statement of over 1/6 patients. \n\nThe answer is contradiction, as the statement is refuted by the actual adverse event statistics provided."}
{"id": "b8322b23-a4f6-4cba-9761-be826b509de7", "result": " Contradiction \n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1: \nTotal: 0/150 (0.00%) \n\nThe SECONDARY TRIAL ADVERSE EVENTS section reports specific adverse events:\n\nEye disorders - Other, Visual disturbance 1/41 (2.44%)\nAbdominal pain 1/41 (2.44%)  \nFebrile neutropenia 1/41 (2.44%)\nAnemia 1/41 (2.44%)\n\nThe statement asserts there were more cases of these adverse events in the secondary trial than the primary trial.\n\nHowever, this contradicts the data presented, as the primary trial reports no adverse events at all to compare to. \n\nTherefore, the comparison described in the statement cannot be validated based on the information given.\n\nThe answer is contradiction, as the assertion is not supported by and conflicts with the trial details provided."}
{"id": "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS sections report over 14 different adverse events across the two cohorts. \n\nThe SECONDARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 2: \nTotal: 1/93 (1.08%)\nDiarrhea 1/93 (1.08%)\n\nThe statement asserts:\n\n- There is only one case of Diarrhea in the secondary trial and over 14 different types of AEs recorded in the primary trial cohorts\n\nThis is directly supported by the adverse event data reported:\n\n- The secondary trial reports 1 case of diarrhea\n- The primary trial reports over 14 different adverse events across its two cohorts\n\nNo conflicting information is presented. The adverse event details precisely match what is claimed in the statement.\n\nTherefore, the statement is entailed by the adverse event descriptions provided for the two trials.\n\nThe answer is entailment, as the adverse event reporting unambiguously validates the assertion."}
{"id": "4b97a844-8d52-48bb-8eda-ca205268f016", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY section lists the inclusion and exclusion criteria:\n\nInclusion criteria include:\n- Life expectancy 1 year. \n\nNo inclusion or exclusion criteria mention a required life expectancy of 75+ years.\n\nThe statement asserts:\n\n- Patients must have a Life expectancy of 75+ years to enroll in the primary trial\n\nHowever, this contradicts the eligibility criteria presented, which specify a life expectancy requirement of only 1 year, not 75+ years.\n\nTherefore, the life expectancy described in the statement does not align with the eligibility details provided.\n\nThe answer is contradiction, as the statement is refuted by the actual eligibility parameters reported. The assertion is not supported."}
{"id": "2a03c17f-3afe-40f1-a0db-4b876ee8c700", "result": "  Entailment\n\nThe PRIMARY TRIAL RESULTS section reports the outcome measurement as:\n\n- Percent Change in Net Influx Constant (Ki) by FLT PET \n\nThe SECONDARY TRIAL RESULTS section reports the outcome measurement as: \n\n- Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)\n\nThe statement asserts:\n\n- The primary trial and the secondary trial have non-comparable outcome measurements for their results\n\nThis is directly supported by the different outcome measurements reported for each trial:\n\n- Percent change in Ki (primary trial)\n- PFS assessed using RECIST (secondary trial)\n\nNo conflicting information is presented. The two distinct outcome measures precisely validate what is claimed in the statement regarding non-comparable results.\n\nTherefore, the statement is entailed by the divergent outcome reporting provided for the primary and secondary trials.\n\nThe answer is entailment, as the results descriptions unambiguously support the assertion."}
{"id": "3ba42f68-a643-4d10-afd0-cbb358d05a6f", "result": " Contradiction\n\nThe PRIMARY TRIAL INTERVENTION sections describe interventions involving:\n\n- BKM120 and Paclitaxel  \n- Placebo and Paclitaxel\n\nThe SECONDARY TRIAL INTERVENTION section describes:\n\n- Active Breathing Coordinator (ABC) device\n\nIt does not provide any information about paclitaxel doses.\n\nThe statement asserts:\n\n- All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial\n\nHowever, this contradicts the intervention details given, as no information is provided about paclitaxel doses in the secondary trial to enable comparison to the primary trial.\n\nTherefore, the relative paclitaxel dosing described in the statement cannot be validated based on the intervention details reported. \n\nThe answer is contradiction, as the assertion is not supported and conflicts with the information provided about the trial interventions."}
{"id": "0a079cca-abde-42cf-9cec-a76e7a380e14", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION section describes the following two interventions:\n\nINTERVENTION 1: \nNo Exercise\nMultivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week\n\nINTERVENTION 2:  \nExercise\nExercise Arm: Exercise consisting of progressive walking and resistance band training \nCalcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise\n\nThe statement asserts:\n\n- Neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention\n\nThis is directly supported by the intervention descriptions provided. Neither intervention involves or requires surgery. \n\nNo contradictory information is presented. The interventions described precisely validate the statement that surgery is not a required part of the interventions.\n\nTherefore, the statement that neither cohort requires surgery is entailed by the intervention details reported for the primary trial.\n\nThe answer is entailment, as the assertion is unambiguously supported by the intervention reporting."}
{"id": "9c033072-5f94-4d79-af47-126d531f0d6e", "result": " Contradiction\n\nThe primary and secondary trial adverse events sections do not report any cases of:\n\n- Holocraneal cephale\n- Catheter - related infections\n\nThe statement asserts:\n\n- There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial\n\nHowever, this contradicts the adverse event data provided, as neither trial reports any cases of these specific adverse events. \n\nTherefore, the comparison described in the statement regarding these two adverse events cannot be validated based on the information given.\n\nThe answer is contradiction, as the assertion is not supported and conflicts with the actual adverse event reporting for the two trials."}
{"id": "a52b2d4f-0b06-4960-a9c3-88cb92df0980", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION section describes:\n\nINTERVENTION 1:\nLapatinib 1250 mg and Capecitabine 2000 mg/m^2\nLapatinib was orally administered at 1250 mg once daily. \nCapecitabine was orally administered at 1000 mg/m^2 twice daily on the first day through the fourteenth day of each 21-day cycle.\n\nThe statement asserts:\n\n- The primary trial participants receive Capecitabine less often than they receive Lapatinib\n\nThis is directly supported by the intervention description, which specifies:\n\n- Lapatinib was administered once daily \n- Capecitabine was administered twice daily, but only from days 1-14 of each 21-day cycle\n\nNo contradictory information is presented. The dosing schedules described for each drug precisely validate the statement that Capecitabine is received less often than Lapatinib.\n\nTherefore, the statement is entailed by the intervention details provided for the primary trial. \n\nThe answer is entailment, as the assertion is unambiguously supported."}
{"id": "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY section lists:\n\nInclusion Criteria:\n- Women >=18 years of age\n\nExclusion Criteria: None specified regarding gender.\n\nThe statement asserts:\n\n- Eliane (56 year old woman) and Alex (32 year old man) can both be eligible for the primary trial\n\nHowever, this contradicts the eligibility criteria stated:\n\n- The inclusion criteria specifies only women >=18 years can enroll \n\n- No mention is made that men can enroll\n\nTherefore, while Eliane may be eligible, Alex cannot based on the gender requirement stated in the inclusion criteria.\n\nThe answer is contradiction, as the statement about both Eliane and Alex being eligible conflicts with the female-only enrollment according to the inclusion criteria provided.\n\nThe assertion is not supported by the trial eligibility details reported."}
{"id": "1842904b-5371-49ee-b6f4-8831b879098b", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1:\nTotal: 11/56 (19.64%)\nFebrile Neutropenia * 3/56 (5.36%) \n\nThe statement asserts:\n\n- Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients\n\nThis is directly supported by the adverse event data reported:\n\n- Febrile Neutropenia affected 3/56 patients or 5.36% \n\n- 5.36% is greater than 5% as stated\n- No other adverse event affected more than 5.36% of patients\n\nNo conflicting information is presented. The adverse event frequencies precisely match what is claimed in the statement.\n\nTherefore, the statement is entailed by the adverse event description provided for the primary trial.\n\nThe answer is entailment, as the adverse event reporting unambiguously validates the assertion."}
{"id": "324562e6-2b61-4a07-b937-86f99689f2d5", "result": "  Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1: \n Diarrhoea 5/65 (7.69%)\n\nThe SECONDARY TRIAL ADVERSE EVENTS sections report: \n\nAdverse Events 1:\nAnaemia 6/472 (1.27%)\n\nThe statement asserts:\n\n- Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial\n\nThis is directly supported by the adverse event frequencies reported:\n\n- Diarrhoea at 5/65 (7.69%) is the most common in the primary trial\n- Anaemia at 6/472 (1.27%) is the most common across the two cohorts in the secondary trial\n\nNo conflicting information is presented. The most frequent adverse events precisely match what is claimed.\n\nTherefore, the statement is entailed by the adverse event descriptions provided for the two trials.\n\nThe answer is entailment, as the assertion is unambiguously validated."}
{"id": "74e376d7-5713-43f3-93f1-9608059c9547", "result": " Contradiction \n\nThe PRIMARY TRIAL RESULTS section reports:\n\nResults 1:\nArm A - Liposomal Doxorubicin Then Docetaxel  \nOverall Response Rate: 28% (16 to 42%)\n\nResults 2: \nArm B - Docetaxel Then Liposomal Doxorubicin\nOverall Response Rate: 31% (18 to 45%)\n\nThe statement asserts:\n\n- Neither intervention resulted in Objective Benefit for >40% of patients \n\n- Over 86% of patients receiving Docetaxel Then Liposomal Doxorubicin suffered fatal complications\n\nHowever, this contradicts the results reported:\n\n- Response rates of 28% and 31% are reported\n- No data is given about fatal complication rates \n\nTherefore, the assertions about response rates and fatal complications in the statement are not supported by the actual results provided.\n\nThe answer is contradiction, as the statement conflicts with the trial outcomes described."}
{"id": "0e609fad-9a28-4fb6-90b6-32a731e3b02c", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS section reports results as:\n\n- Percentage of participants \n- Unit of measure: percentage of participants 26 (13 to 44) \n\nThe SECONDARY TRIAL RESULTS section reports results as:\n\n- Proportion of Sentinel Lymph Nodes (SLNs)  \n- Unit of measure: proportion of nodes\n\nThe statement asserts:\n\n- The primary trial and secondary trial report their results as percentages but use different units of measure\n\nThis is directly supported by the information provided:\n\n- Primary trial reports results as a percentage \n- Secondary trial reports results as a proportion\n- Percentage and proportion are both units that express a number as a fraction of 100\n\nNo conflicting details are presented. The reporting of results using percentage for one trial and proportion for the other precisely matches the claim.\n\nTherefore, the statement is entailed by the divergent units used to report outcomes between the two trials.\n\nThe answer is entailment, as the results descriptions unambiguously validate the assertion."}
{"id": "236780db-9e59-4dc9-8da0-e786287011cf", "result": " Contradiction\n\nThe PRIMARY TRIAL INTERVENTION section describes:\n\nINTERVENTION 1:\nPemetrexed \n600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression\n\nThe statement asserts: \n\n- The primary trial intervention protocol lasts a total of 14 days\n\nHowever, this contradicts the intervention details provided:\n\n- Pemetrexed is administered every 14 days, not for a total of 14 days\n- It specifies administration will continue until complete response or disease progression, not a fixed 14 day period\n\nThe intervention description does not validate or support that the protocol only lasts 14 days total as stated. \n\nTherefore, the statement conflicts with the duration described for the intervention in the primary trial.\n\nThe answer is contradiction, as the assertion is not supported and contradicts the information given about the length of the intervention protocol."}
{"id": "6d621974-c719-46df-8a50-d94e49583e33", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY section lists:\n\nInclusion Criteria:\n- Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization.\n\nThe statement asserts: \n\n- All patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\n\nHowever, this contradicts the eligibility criteria stated:\n\n- Prior endocrine therapy is permitted but must be discontinued at randomization \n\n- It does not require or state that all patients must have received prior endocrine therapy\n\nTherefore, the statement that all patients must have received prior endocrine therapy is not supported and contradicts the eligibility criteria outlined.\n\nThe answer is contradiction, as the assertion conflicts with the information provided about trial eligibility."}
{"id": "a9907a2e-254a-45ca-af50-3e44fd2f7af3", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1: \nNeutropenia 1/39 (2.56%)\n\nAdverse Events 2:\nNeutropenia 1/21 (4.76%)\n\nThe statement asserts: \n\n- There was one case of Neutropenia in both cohorts of the primary trial\n\nThis is directly supported by the adverse event frequencies reported:\n\n- Neutropenia affected 1/39 patients in cohort 1  \n- Neutropenia affected 1/21 patients in cohort 2\n\nNo conflicting information is presented. The occurrence of one case of Neutropenia in each cohort precisely matches what is claimed.\n\nTherefore, the statement is entailed by the adverse event descriptions provided for the two cohorts in the primary trial. \n\nThe answer is entailment, as the assertion is unambiguously validated by the adverse event reporting."}
{"id": "40f699a1-fbc6-40de-8e80-85b28f71632f", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS section reports: \n\nResults 1:\nArm - Trastuzumab Emtansine\nGrade 1: 53 75.7%\nGrade 2: 40 57.1% \nGrade 3: 18 25.7%\nGrade 4: 2 2.9%  \nGrade 5: 12 17.1%\n\nThe statement asserts:\n\n- Most patients experienced Grade 1 AEs \n- Grade 5 was the least common and only affected 8/70 patients\n\nHowever, this contradicts the results reported:\n\n- Grade 1 was experienced by 53/70 patients, not most  \n- Grade 5 affected 12/70 patients, not 8/70\n\nTherefore, the statement about the frequency of different grade adverse events does not match the data presented and is contradictory.\n\nThe answer is contradiction, as the assertion conflicts with the adverse event severity reporting in the results."}
{"id": "6499b181-7a23-4073-8459-ad46ff02b20f", "result": " Contradiction\n\nThe PRIMARY TRIAL INTERVENTION section describes:\n\nINTERVENTION 1: \n- Each treatment cycle is 28 days\n- Participants will be treated until disease progression\n\nThe statement asserts:\n\n- Participants will receive the intervention for a total of 12 cycles (28 days)\n\nHowever, this contradicts the intervention details provided:\n\n- Treatment cycles are every 28 days \n- Participants will be treated until disease progression, not for a fixed number of cycles\n\nThe intervention description does not specify treatment will be given for exactly 12 cycles as stated.\n\nTherefore, the statement that participants will receive the intervention for a total of 12 cycles conflicts with the information provided about treatment duration in the primary trial.\n\nThe answer is contradiction, as the assertion is not supported and contradicts the length of treatment described."}
{"id": "2da13cd4-7189-4f85-be4d-5c1e213ae293", "result": " Contradiction\n\nThe PRIMARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1:\nNon-cardiac chest pain 2/61 (3.28%)\n\nThe statement asserts:\n\n- The most common AE was Non-cardiac chest pain, which affected <5% of participants in cohort 1\n\nHowever, this contradicts the adverse event data reported:\n\n- Non-cardiac chest pain affected 2/61 participants or 3.28% in cohort 1\n- 3.28% is not less than 5% as stated\n\nTherefore, the statement that Non-cardiac chest pain affected less than 5% of participants in cohort 1 is contradictory to the frequency reported in the adverse event table.\n\nThe answer is contradiction, as the assertion conflicts with the actual adverse event rate described."}
{"id": "a9bb6de9-c6f8-4c99-81cd-f101cbaab387", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY section lists the following inclusion criteria:\n\n- Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain\n- Extracranial metastases allowed\n\nThe statement asserts:\n\n- Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial\n\nHowever, this directly contradicts the eligibility criteria stated, which explicitly requires that patients must have radiographically confirmed brain metastases.\n\nHaving brain metastases is a requirement, not an exclusion criterion. The statement that patients cannot have brain metastases is thus not supported and conflicts with the eligibility details provided.\n\nTherefore, the answer is contradiction, as the statement is contradicted by the eligibility criteria described for the primary trial."}
{"id": "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7", "result": "  Entailment\n\nThe PRIMARY TRIAL RESULTS section reports:\n\nOutcome Measurement: \n- Complete Response (CR), Disappearance of all target lesions\n- Partial Response (PR), >=30% decrease in target lesions  \n- Stable Disease (SD), a tumor that is neither growing nor shrinking\n\nResults 1:\n- Sorafenib and Anastrozole arm\n- Number of participants analyzed: 35  \n- Measure (Unit of Measure): 35 participants\n\nThe statement asserts:\n\n- All primary trial patients achieved CR, PR or SD\n\nThis is directly supported by the results reported:\n\n- 35 participants are reported as the measure\n- This implies all 35 patients achieved the defined clinical outcomes of CR, PR or SD\n\nNo conflicting information is presented. The statement precisely matches the implication of the results reported.\n\nTherefore, the statement is entailed by the outcome definitions and results provided for the primary trial.\n\nThe answer is entailment, as the assertion is unambiguously validated."}
{"id": "016943fa-57ea-4293-8131-03292ea1836c", "result": " Entailment\n\nThe PRIMARY TRIAL ELIGIBILITY section lists the following inclusion criteria:\n\n- Node-positive: T1-3, N1-2, M0\n- Node-negative AND tumor >2 cm \n\nThe statement asserts:\n\n- A patient with a node positive T2 N2 M0 adenocarcinoma would be eligible\n- A patient with a node negative adenocarcinoma with a tumor diameter of over 2cm would be eligible\n\nThese criteria precisely match two of the eligibility criteria outlined:\n\n- T2 N2 M0 satisfies the node-positive criteria of T1-3, N1-2, M0\n- A tumor diameter over 2cm satisfies the node-negative criteria\n\nNo conflicting information is presented. The stated patient characteristics directly align with and validate the eligibility criteria described. \n\nTherefore, the statement is entailed by the inclusion criteria provided for patient tumor characteristics.\n\nThe answer is entailment, as the assertion is unambiguously supported."}
{"id": "402f0dbf-cf67-4425-b300-a0a3df4d59d3", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS section reports:\n\nOutcome Measurement: Objective Response Rate (ORR) \n\nThe SECONDARY TRIAL RESULTS section reports:\n\nOutcome Measurement: Objective Response (OR)\n\nThe statement asserts:\n\n- The secondary trial and primary trial use Objective Response as the outcome measurement.\n\nThis is directly supported by the information provided:\n\n- Both trials report using Objective Response/Rate as their outcome measurement.\n\nNo conflicting details are presented. The use of the same outcome measurement, Objective Response, precisely matches what is claimed.\n\nTherefore, the statement is entailed as the outcome measurements described for both trials unambiguously validate the assertion.\n\nThe answer is entailment, as the trials are shown to use the same outcome measurement as stated."}
{"id": "62be4676-099f-4c42-8029-773af8fde6f7", "result": " Contradiction\n\nThe PRIMARY TRIAL ELIGIBILITY section lists the following inclusion criteria:\n\n- ECOG performance status =< 2 (Karnofsky >= 60%)\n- No mention of patients needing to be bedbound or severely disabled\n\nThe statement asserts:\n\n- Patients must be bedbound or severely disabled to participate\n\nHowever, this contradicts the eligibility criteria provided:\n\n- An ECOG score of 0-2 allows for restricted activity but not bedbound or disabled patients  \n- There is no criteria stating patients must be bedbound or disabled\n\nThe eligibility section does not support that patients need to be bedbound or severely disabled as claimed. Therefore, the statement conflicts with the trial eligibility described.\n\nThe answer is contradiction, as the assertion is contradicted by the information given about patient eligibility."}
{"id": "1180dd58-61b8-4c48-ab00-7d458e68c85b", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS section reports outcome measurement as: \n\nSafety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks\n\nThe SECONDARY TRIAL RESULTS section reports outcome measurement as:\n\nOverall Tumor Response\n\nThe statement asserts:\n\n- The results of the secondary trial and primary trial report the same outcome measures\n\nHowever, this is contradictory as the trials report different outcome measurements:\n\n- Primary trial measures safety \n- Secondary trial measures tumor response\n\nNo part of the reported results align the outcome measurements between the two trials.\n\nTherefore, the statement that the trials report the same outcome measures is contradicted by the results sections showing they measure different endpoints.\n\nThe answer is contradiction, as the assertion conflicts with the distinct outcome measurements described for each trial."}
{"id": "566bdc2d-7c4a-4547-87da-ac81447ecca8", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS section reports:\n\nResults 1: \nArm: Lapatinib Plus Capecitabine\nNumber of participants with CNS metastases: 8\n\nResults 2:  \nArm: Trastuzumab Plus Capecitabine\nNumber of participants with CNS metastases: 12\n\nThe statement asserts:\n\n- The Trastuzumab Plus Capecitabine group had a higher percentage of Grade 3/4 skin/subcutaneous or pulmonary toxicities \n\nHowever, this contradicts the results reported:\n\n- The results report numbers of participants with CNS metastases, not toxicities\n- No data on toxicities is provided to compare between the two groups\n\nThe statement claims a difference in adverse event rates, but the trial results presented do not include any adverse event data to validate this. \n\nTherefore, the statement is contradicted as it does not align with the outcome measurement and results described for the primary trial.\n\nThe answer is contradiction, as the assertion is not supported by the information given."}
{"id": "d310ec4e-993e-4827-8dc5-9aca053972db", "result": " Entailment\n\nThe PRIMARY TRIAL INTERVENTION section reports:\n\nIntervention 1: \nLetrozole 2.5 mg orally once daily for 24 weeks\n\nThe SECONDARY TRIAL INTERVENTION section reports: \n\nIntervention 1:\nSentinel Lymph Node Biopsy\n\nThe statement asserts:\n\n- The primary trial intervention involves one drug taken orally\n- The secondary trial intervention is based on a medical procedure\n\nThis is directly supported by the information provided:\n\n- The primary trial intervention involves Letrozole, a drug, taken orally\n- The secondary trial intervention is a sentinel lymph node biopsy, a medical procedure\n\nNo conflicting details are presented. The interventions described precisely match the distinction made in the statement between a drug and procedure intervention.\n\nTherefore, the statement is entailed as the intervention types for each trial unambiguously validate the assertion. \n\nThe answer is entailment, as the interventions reported support the claims made."}
{"id": "a5617ae4-05a3-42d0-9e14-141de5f8c010", "result": " Entailment\n\nThe PRIMARY TRIAL ADVERSE EVENTS section does not report any cases of conjunctivitis. \n\nThe SECONDARY TRIAL ADVERSE EVENTS section reports:\n\nAdverse Events 1: \nConjunctivitis 0/519 (0.00%)\n\nAdverse Events 2:  \nConjunctivitis 1/532 (0.19%)\n\nThe statement asserts:\n\n- The secondary trial reported 1 single case of conjunctivitis, whereas the primary trial did not report any.\n\nThis is directly supported by the adverse event tables:\n\n- The primary trial does not report conjunctivitis cases \n- The secondary trial reports 1 case of conjunctivitis\n\nNo conflicting information is presented. The adverse event reporting precisely matches the statement made.\n\nTherefore, the statement is unequivocally entailed by the adverse event data provided for the two trials.\n\nThe answer is entailment, as the assertion is unambiguously validated."}
{"id": "42d1fcd3-8faa-4065-bbba-42cc90ab67fb", "result": "  Entailment\n\nThe PRIMARY TRIAL RESULTS section reports outcome measurement as:\n\nNumber of Patients With Pathological Complete Response Rate \n\nThe SECONDARY TRIAL RESULTS section reports outcome measurement as: \n\nDisease Free Survival. Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years\n\nThe statement asserts:\n\n- The secondary trial and primary trial do not both measure the pCR of their patient cohorts.\n\nThis is directly supported by the information provided, as the trials report measuring different outcomes:\n\n- Primary trial measures pCR\n- Secondary trial measures disease free survival\n\nNo part of the reported results shows the trials both measure pCR. \n\nTherefore, the statement that the trials do not both measure pCR is unequivocally entailed by the distinct outcome measurements described.\n\nThe answer is entailment, as the results sections validate the claim."}
{"id": "d01fda83-5dc8-4ad5-92b8-7553dabd7046", "result": " Entailment\n\nThe PRIMARY TRIAL RESULTS section reports the outcome measurement as: \n\nProgression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.\n\nThe statement asserts:\n\n- The outcome measurement is the length of time during and after treatment that a patient lives with the disease but it does not get worse.\n\nThis directly matches the definition of progression-free survival - the length of time during and after treatment that the disease does not get worse.\n\nNo conflicting information is presented. The outcome measurement described precisely aligns with the statement made.\n\nTherefore, the statement is unequivocally entailed as the primary outcome reported validates what is claimed about measuring progression-free survival.\n\nThe answer is entailment, as the assertion is unambiguously supported by the trial results."}
{"id": "985bc5a0-bc21-447f-92f1-150e23ede3f5", "result": " Contradiction\n\nThe PRIMARY TRIAL RESULTS section reports the outcome measurement as:\n\nComplete Response + Partial Response + Stable Disease > 24 Weeks\n\nWhere:\n\n- Partial Response is defined as >=30% decrease in the sum of the longest diameter of target lesions \n\nThe statement asserts:\n\n- All patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions\n\nHowever, this contradicts the definition of Partial Response provided in the trial, which only requires a >=30% decrease. \n\nNo results are given that specify all patients had >=50% decrease as claimed. The definition given does not support this higher threshold.\n\nTherefore, the statement is contradicted as the criteria reported do not validate that all patients met the 50% decrease level mentioned.\n\nThe answer is contradiction, as the assertion conflicts with the information presented."}
